Protein	protein	NN	O
kinases	kinase	NNS	O
constitute	constitute	VBP	O
one	one	CD	O
of	of	IN	O
the	the	DT	O
largest	large	JJS	O
protein	protein	NN	O
families	family	NNS	O
in	in	IN	O
humans	human	NNS	B
.	.	.	O

The	the	DT	O
kinase	kinase	NN	O
enzymes	enzyme	NNS	O
in	in	IN	O
this	this	DT	O
family	family	NN	O
catalyse	catalyse	NN	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
serine	serine	NNP	O
,	,	,	O
threonine	threonine	NN	O
,	,	,	O
or	or	CC	O
tyrosine	tyrosine	NN	O
residues	residue	NNS	O
,	,	,	O
which	which	WDT	O
regulate	regulate	VBP	O
the	the	DT	O
majority	majority	NN	O
of	of	IN	O
signal	signal	JJ	O
transduction	transduction	NN	O
pathways	pathway	NNS	O
in	in	IN	O
cell	cell	NN	O
,	,	,	O
and	and	CC	O
thus	thus	RB	O
play	play	VB	O
an	an	DT	O
important	important	JJ	O
role	role	NN	O
in	in	IN	O
cell	cell	NN	O
growth	growth	NN	O
,	,	,	O
metabolism	metabolism	NN	O
,	,	,	O
differentiation	differentiation	NN	O
and	and	CC	O
apoptosis	apoptosis	NN	O
consequently	consequently	RB	O
.	.	.	O

Deregulation	deregulation	NN	O
of	of	IN	O
protein	protein	NN	O
kinases	kinase	NNS	O
is	be	VBZ	O
implicated	implicate	VBN	O
in	in	IN	O
a	a	DT	O
number	number	NN	O
of	of	IN	O
diseases	disease	NNS	O
including	include	VBG	O
cancer	cancer	NN	O
,	,	,	O
diabetes	diabetes	NN	O
and	and	CC	O
inflammation	inflammation	NN	O
.	.	.	O

Targeted	target	VBN	O
inhibition	inhibition	NN	O
of	of	IN	O
protein	protein	NN	O
kinases	kinase	NNS	O
has	have	VBZ	O
thereby	thereby	RB	O
become	become	VBN	O
an	an	DT	O
attractive	attractive	JJ	O
therapeutic	therapeutic	JJ	O
strategy	strategy	NN	O
in	in	IN	O
treatment	treatment	NN	O
of	of	IN	O
relevant	relevant	JJ	O
diseases	disease	NNS	B
,	,	,	B
.	.	.	O

Fibroblast	fibroblast	JJ	O
growth	growth	NN	O
-	-	HYPH	O
factor	factor	NN	O
receptors	receptor	NNS	O
form	form	VBP	O
a	a	DT	O
sub	sub	NN	O
-	-	NN	O
family	family	NN	O
of	of	IN	O
the	the	DT	O
receptor	receptor	NN	O
tyrosine	tyrosine	NN	O
kinase	kinase	NNP	O
superfamily	superfamily	RB	O
,	,	,	O
which	which	WDT	O
consists	consist	VBZ	O
of	of	IN	O
four	four	CD	O
highly	highly	RB	O
conserved	conserve	VBN	O
functional	functional	JJ	O
members	member	NNS	O
FGFR	FGFR	NNP	O
1â4	1â4	CD	O
)	)	-RRB-	B
,	,	,	B
.	.	.	O

FGFR	fgfr	NN	O
signalling	signalling	NN	O
is	be	VBZ	O
initiated	initiate	VBN	O
by	by	IN	O
binding	bind	VBG	O
of	of	IN	O
extracellular	extracellular	NNP	O
FGF	FGF	NNP	O
ligand	ligand	NN	O
which	which	WDT	O
leads	lead	VBZ	O
to	to	IN	O
receptor	receptor	NN	O
dimerisation	dimerisation	NN	O
and	and	CC	O
cross	cross	NN	O
-	-	NN	O
phosphorylation	phosphorylation	NN	O
of	of	IN	O
the	the	DT	O
kinase	kinase	NN	O
domains	domain	NNS	O
proceed	proceed	VBP	O
to	to	TO	O
phosphorylate	phosphorylate	VB	O
intracellular	intracellular	JJ	O
substrates	substrate	NNS	O
such	such	JJ	O
as	as	IN	O
FRS2	FRS2	NNP	O
,	,	,	O
Gab1	Gab1	NNP	O
,	,	,	O
PLCÎ³	plcî³	NN	O
,	,	,	O
and	and	CC	O
STAT1	stat1	NN	O
.	.	.	O

Subsequent	subsequent	JJ	O
downstream	downstream	JJ	O
signalling	signalling	NN	O
is	be	VBZ	O
complex	complex	JJ	O
and	and	CC	O
includes	include	VBZ	O
activation	activation	NN	O
of	of	IN	O
the	the	DT	O
PI3K	PI3K	NNP	O
-	-	HYPH	O
Akt	Akt	NNP	O
and	and	CC	O
the	the	DT	O
Ras	Ras	NNP	O
/	/	SYM	O
Raf	Raf	NNP	O
/	/	SYM	O
Mek	Mek	NNP	O
/	/	SYM	O
Erk	Erk	NNP	O
pathways	pathway	NNS	O
.	.	.	O

In	in	IN	O
normal	normal	JJ	O
cells	cell	NNS	O
,	,	,	O
FGFR	FGFR	NNP	O
plays	play	VBZ	O
fundamental	fundamental	JJ	O
roles	role	NNS	O
in	in	IN	O
many	many	JJ	O
physiologic	physiologic	JJ	O
processes	process	NNS	O
,	,	,	O
including	include	VBG	O
embryogenesis	embryogenesis	NN	O
,	,	,	O
tissue	tissue	NN	O
homeostasis	homeostasis	NN	O
,	,	,	O
tissue	tissue	NN	O
repairing	repairing	NN	O
,	,	,	O
wound	wind	VBN	O
healing	healing	NN	O
,	,	,	O
and	and	CC	O
inflammation	inflammation	NN	B
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
the	the	DT	O
inhibition	inhibition	NN	O
of	of	IN	O
FGFR	FGFR	NNP	O
signalling	signal	VBG	O
pathway	pathway	NN	O
presents	present	VBZ	O
a	a	DT	O
promising	promising	JJ	O
option	option	NN	O
for	for	IN	O
cancer	cancer	NN	O
therapeutics	therapeutic	NNS	O
.	.	.	O

In	in	IN	O
the	the	DT	O
past	past	JJ	O
few	few	JJ	O
years	year	NNS	O
,	,	,	O
different	different	JJ	O
strategies	strategy	NNS	O
have	have	VBP	O
been	be	VBN	O
pursued	pursue	VBN	O
to	to	TO	O
inhibit	inhibit	VB	O
abnormal	abnormal	JJ	O
FGFR	fgfr	NN	O
signalling	signal	VBG	O
pathways	pathway	NNS	O
,	,	,	O
among	among	IN	O
them	-PRON-	PRP	O
several	several	JJ	O
small	small	JJ	O
-	-	HYPH	O
molecule	molecule	NN	O
FGFR	FGFR	NNP	O
inhibitors	inhibitor	NNS	O
have	have	VBP	O
advanced	advance	VBN	O
into	into	IN	O
clinical	clinical	JJ	O
trial	trial	NN	B
.	.	.	O

While	while	IN	O
the	the	DT	O
pan	pan	NN	O
-	-	HYPH	O
kinase	kinase	JJ	O
inhibitors	inhibitor	NNS	O
e.g.	e.g.	RB	O
dovitinib	dovitinib	NNP	B
,	,	,	O
nintedanib	nintedanib	NNP	B
,	,	,	O
and	and	CC	O
ponatinib	ponatinib	JJ	B
which	which	WDT	O
were	be	VBD	O
originally	originally	RB	O
adopted	adopt	VBN	O
for	for	IN	O
the	the	DT	O
treatment	treatment	NN	O
of	of	IN	O
cancers	cancer	NNS	O
that	that	WDT	O
harbour	harbour	VBP	O
aberrant	aberrant	JJ	O
FGFR	FGFR	NNP	O
,	,	,	O
severe	severe	JJ	O
side	side	NN	O
effects	effect	NNS	O
were	be	VBD	O
observed	observe	VBN	O
due	due	IN	O
to	to	IN	O
inhibition	inhibition	NN	O
of	of	IN	O
several	several	JJ	O
off	off	IN	O
-	-	HYPH	O
target	target	NN	O
kinases	kinase	NNS	O
such	such	JJ	O
as	as	IN	O
EGFR	EGFR	NNP	O
,	,	,	O
VEGFR	VEGFR	NNP	O
,	,	,	O
PDGFR	PDGFR	NNP	O
,	,	,	O
etc	etc	FW	O
.	.	.	O

More	more	RBR	O
recently	recently	RB	O
,	,	,	O
there	there	EX	O
has	have	VBZ	O
been	be	VBN	O
an	an	DT	O
increasing	increase	VBG	O
interest	interest	NN	O
in	in	IN	O
developing	develop	VBG	O
selective	selective	JJ	O
FGFR	FGFR	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

Several	several	JJ	O
selective	selective	JJ	O
FGFR	FGFR	NNP	O
inhibitors	inhibitor	NNS	O
bear	bear	VBP	O
various	various	JJ	O
scaffolds	scaffold	NNS	O
have	have	VBP	O
been	be	VBN	O
developed	develop	VBN	O
into	into	IN	O
clinical	clinical	JJ	O
investigation	investigation	NN	O
.	.	.	O

Structure	structure	NN	O
of	of	IN	O
representative	representative	JJ	O
FGFR	FGFR	NNP	O
inhibitors	inhibitor	NNS	O
.	.	.	O

In	in	IN	O
our	-PRON-	PRP$	O
previous	previous	JJ	O
studies	study	NNS	O
,	,	,	O
a	a	DT	O
series	series	NN	O
of	of	IN	O
indazole	indazole	NN	O
derivatives	derivative	NNS	O
were	be	VBD	O
discovered	discover	VBN	O
as	as	IN	O
potent	potent	JJ	O
FGFR1	fgfr1	CD	O
inhibitors	inhibitor	NNS	B
.	.	.	O

The	the	DT	O
most	most	RBS	O
promising	promising	JJ	O
compound	compound	NN	O
L1	L1	NNP	O
exhibited	exhibit	VBD	O
good	good	JJ	O
enzymatic	enzymatic	JJ	O
inhibition	inhibition	NN	O
against	against	IN	O
FGFR1	fgfr1	CD	O
and	and	CC	O
modest	modest	JJ	O
cellular	cellular	JJ	O
inhibition	inhibition	NN	O
.	.	.	O

In	in	IN	O
this	this	DT	O
study	study	NN	O
,	,	,	O
in	in	IN	O
order	order	NN	O
to	to	TO	O
improve	improve	VB	O
the	the	DT	O
cellular	cellular	JJ	O
inhibition	inhibition	NN	O
,	,	,	O
discover	discover	VBP	O
novel	novel	NN	O
scaffold	scaffold	NN	O
and	and	CC	O
enrich	enrich	VB	O
the	the	DT	O
structure	structure	NN	O
-	-	HYPH	O
activity	activity	NN	O
relationship	relationship	NN	O
,	,	,	O
further	further	JJ	O
work	work	NN	O
has	have	VBZ	O
been	be	VBN	O
putting	put	VBG	O
into	into	IN	O
modification	modification	NN	O
of	of	IN	O
indazole	indazole	NNP	O
scaffold	scaffold	NNP	O
and	and	CC	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
substituents	substituent	NNS	O
.	.	.	O

The	the	DT	O
goal	goal	NN	O
of	of	IN	O
this	this	DT	O
compound	compound	NN	O
modification	modification	NN	O
was	be	VBD	O
to	to	TO	O
increase	increase	VB	O
the	the	DT	O
ligand	ligand	NN	O
-	-	HYPH	O
receptor	receptor	NN	O
interaction	interaction	NN	O
,	,	,	O
and	and	CC	O
improve	improve	VB	O
the	the	DT	O
physico	physico	NN	O
-	-	HYPH	O
chemical	chemical	NN	O
property	property	NN	O
.	.	.	O

As	as	IN	O
a	a	DT	O
result	result	NN	O
,	,	,	O
we	-PRON-	PRP	O
designed	design	VBD	O
the	the	DT	O
novel	novel	JJ	O
FGFR1	FGFR1	NNS	O
inhibitors	inhibitor	NNS	O
by	by	IN	O
the	the	DT	O
following	follow	VBG	O
two	two	CD	O
strategies	strategy	NNS	O
:	:	:	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
fragment	fragment	NN	O
-	-	HYPH	O
based	base	VBN	O
drug	drug	NN	O
design	design	NN	O
strategy	strategy	NN	O
,	,	,	O
we	-PRON-	PRP	O
introduced	introduce	VBD	O
novel	novel	JJ	O
flat	flat	JJ	O
hetero	hetero	NNP	O
aromatic	aromatic	JJ	O
ring	ring	NN	O
which	which	WDT	O
formed	form	VBD	O
key	key	JJ	O
H	h	NN	O
-	-	HYPH	O
bond	bond	NN	O
interaction	interaction	NN	O
with	with	IN	O
hinge	hinge	NN	O
region	region	NN	O
;	;	:	O
further	further	JJ	O
optimisation	optimisation	NN	O
of	of	IN	O
the	the	DT	O
original	original	JJ	O
indazole	indazole	NN	O
inhibitors	inhibitor	NNS	O
via	via	IN	O
introduced	introduce	VBN	O
halogen	halogen	NN	O
atoms	atom	NNS	O
,	,	,	O
that	that	WDT	O
were	be	VBD	O
often	often	RB	O
used	use	VBN	O
to	to	TO	O
improve	improve	VB	O
permeability	permeability	NN	O
through	through	IN	O
the	the	DT	O
modulation	modulation	NN	O
of	of	IN	O
modulation	modulation	NN	O
of	of	IN	O
compoundâs	compoundâs	CD	O
lipophilicity	lipophilicity	NN	O
and	and	CC	O
halogen	halogen	NN	O
-	-	HYPH	O
protein	protein	NN	O
interactions	interaction	NNS	O
.	.	.	O

Herein	Herein	NNP	O
,	,	,	O
with	with	IN	O
the	the	DT	O
fragment	fragment	NN	O
-	-	HYPH	O
based	base	VBN	O
virtual	virtual	JJ	O
screening	screening	NN	O
strategy	strategy	NN	O
,	,	,	O
we	-PRON-	PRP	O
designed	design	VBD	O
three	three	CD	O
novel	novel	JJ	O
series	series	NN	O
of	of	IN	O
FGFR1	FGFR1	NNP	O
inhibitors	inhibitor	NNS	O
bearing	bear	VBG	O
1H-1,2,4-triazole	1h-1,2,4-triazole	CD	O
,	,	,	O
benzothiazole	benzothiazole	NNP	O
and	and	CC	O
indazole	indazole	NN	O
scaffold	scaffold	NN	O
Figure	Figure	NNP	O
2	2	CD	O
.	.	.	O

The	the	DT	O
indazole	indazole	NN	O
derivative	derivative	JJ	O
9âu	9âu	CD	O
stood	stand	VBD	O
out	out	RP	O
as	as	IN	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
FGFR1	fgfr1	JJ	O
inhibitor	inhibitor	NN	O
,	,	,	O
and	and	CC	O
it	-PRON-	PRP	O
also	also	RB	O
exhibited	exhibit	VBD	O
good	good	JJ	O
kinase	kinase	NN	O
selectivity	selectivity	NN	O
.	.	.	O

Additionally	additionally	RB	O
,	,	,	O
the	the	DT	O
docking	docking	NN	O
studies	study	NNS	O
were	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
to	to	TO	O
investigate	investigate	VB	O
the	the	DT	O
receptor	receptor	NN	O
-	-	HYPH	O
ligand	ligand	NN	O
interaction	interaction	NN	O
.	.	.	O

Binding	bind	VBG	O
model	model	NN	O
of	of	IN	O
AZD4547	AZD4547	NNP	O
and	and	CC	O
NVP	NVP	NNP	O
-	-	HYPH	O
BGJ398	BGJ398	NNP	O
to	to	IN	O
the	the	DT	O
FGFR1	fgfr1	CD	O
kinase	kinase	NN	O
domain	domain	NN	O
.	.	.	O

The	the	DT	O
fragment	fragment	NN	O
-	-	HYPH	O
based	base	VBN	O
virtual	virtual	JJ	O
screening	screening	NN	O
protocol	protocol	NN	O
.	.	.	O

The	the	DT	O
fragment	fragment	NN	O
library	library	NN	O
was	be	VBD	O
derived	derive	VBN	O
from	from	IN	O
kinase	kinase	NNP	O
hinge	hinge	NN	O
region	region	NN	O
directed	direct	VBN	O
library	library	NN	O
provided	provide	VBN	O
by	by	IN	O
enamine	enamine	NN	O
,	,	,	O
which	which	WDT	O
contained	contain	VBD	O
11809	11809	CD	O
fragments	fragment	NNS	O
.	.	.	O

On	on	IN	O
the	the	DT	O
basis	basis	NN	O
of	of	IN	O
the	the	DT	O
chemical	chemical	NN	O
features	feature	NNS	O
of	of	IN	O
FGFR1	fgfr1	CD	O
inhibitors	inhibitor	NNS	O
,	,	,	O
these	these	DT	O
pharmacophore	pharmacophore	NN	O
features	feature	NNS	O
,	,	,	O
hydrogen	hydrogen	NNP	O
bond	bond	NNP	O
acceptor	acceptor	NN	O
,	,	,	O
hydrogen	hydrogen	NNP	O
bond	bond	NN	O
donor	donor	NN	O
,	,	,	O
and	and	CC	O
hydrophobic	hydrophobic	NN	O
were	be	VBD	O
defined	define	VBN	O
as	as	IN	O
a	a	DT	O
query	query	NN	O
for	for	IN	O
pharmacophore	pharmacophore	NN	O
screening	screening	NN	O
.	.	.	O

The	the	DT	O
database	database	NN	O
screening	screening	NN	O
was	be	VBD	O
performed	perform	VBN	O
using	use	VBG	O
the	the	DT	O
Ligand	Ligand	NNP	O
Pharmacophore	Pharmacophore	NNP	O
Mapping	Mapping	NNP	O
protocol	protocol	NN	O
in	in	IN	O
DS	DS	NNP	O
4.0	4.0	CD	O
.	.	.	O

The	the	DT	O
fit	fit	JJ	O
values	value	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
based	base	VBN	O
on	on	IN	O
the	the	DT	O
chemical	chemical	NN	O
substructures	substructure	NNS	O
map	map	VBP	O
the	the	DT	O
location	location	NN	O
constraints	constraint	NNS	O
of	of	IN	O
the	the	DT	O
pharmacophoric	pharmacophoric	JJ	O
features	feature	NNS	O
and	and	CC	O
their	-PRON-	PRP$	O
distance	distance	NN	O
deviation	deviation	NN	O
from	from	IN	O
the	the	DT	O
feature	feature	NN	O
centres	centre	NNS	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
only	only	RB	O
the	the	DT	O
compounds	compound	NNS	O
showed	show	VBD	O
good	good	JJ	O
fit	fit	JJ	O
values	value	NNS	O
in	in	IN	O
pharmacophore	pharmacophore	NN	O
model	model	NN	O
could	could	MD	O
enter	enter	VB	O
the	the	DT	O
further	further	JJ	O
molecular	molecular	JJ	O
docking	docking	NN	O
study	study	NN	O
.	.	.	O

Molecular	molecular	JJ	O
docking	docking	NN	O
of	of	IN	O
compounds	compound	NNS	O
into	into	IN	O
the	the	DT	O
three	three	CD	O
dimensional	dimensional	JJ	O
X	x	NN	O
-	-	NN	O
ray	ray	NN	O
structure	structure	NN	O
of	of	IN	O
FGFR1	fgfr1	CD	O
was	be	VBD	O
carried	carry	VBN	O
out	out	RP	O
using	use	VBG	O
the	the	DT	O
surflex	surflex	JJ	O
-	-	HYPH	O
dock	dock	NN	O
module	module	NN	O
of	of	IN	O
the	the	DT	O
Sybyl	Sybyl	NNP	O
-	-	HYPH	O
x	x	NNP	O
2.0	2.0	CD	O
software	software	NN	O
package	package	NN	O
.	.	.	O

The	the	DT	O
three	three	CD	O
-	-	HYPH	O
dimensional	dimensional	JJ	O
structure	structure	NN	O
of	of	IN	O
compound	compound	NN	O
was	be	VBD	O
constructed	construct	VBN	O
using	use	VBG	O
ChemBio	ChemBio	NNP	O
3âD	3âd	CD	O
Ultra	Ultra	NNP	O
software	software	NN	O
,	,	,	O
then	then	RB	O
it	-PRON-	PRP	O
was	be	VBD	O
energetically	energetically	RB	O
minimised	minimise	VBN	O
by	by	IN	O
using	use	VBG	O
MMFF94	MMFF94	NNP	O
with	with	IN	O
5000	5000	CD	O
iterations	iteration	NNS	O
and	and	CC	O
minimum	minimum	JJ	O
RMS	RMS	NNP	O
gradient	gradient	NN	O
0.05	0.05	CD	O
.	.	.	O

The	the	DT	O
protein	protein	NN	O
was	be	VBD	O
prepared	prepare	VBN	O
by	by	IN	O
the	the	DT	O
Protein	Protein	NNP	O
preparation	preparation	NN	O
wizard	wizard	NN	O
of	of	IN	O
Sybyl	Sybyl	NNP	O
-	-	HYPH	O
x	x	NNP	O
2.0	2.0	CD	O
.	.	.	O

The	the	DT	O
waters	water	NNS	O
were	be	VBD	O
eliminated	eliminate	VBN	O
from	from	IN	O
the	the	DT	O
protein	protein	NN	O
and	and	CC	O
the	the	DT	O
polar	polar	JJ	O
hydrogen	hydrogen	NN	O
was	be	VBD	O
added	add	VBN	O
.	.	.	O

Receptor	receptor	NN	O
grids	grid	NNS	O
were	be	VBD	O
generated	generate	VBN	O
using	use	VBG	O
Receptor	Receptor	NNP	O
Grid	Grid	NNP	O
Generation	Generation	NNP	O
.	.	.	O

The	the	DT	O
generated	generate	VBN	O
binding	bind	VBG	O
site	site	NN	O
was	be	VBD	O
just	just	RB	O
the	the	DT	O
ATP	atp	NN	O
-	-	HYPH	O
binding	bind	VBG	O
pocket	pocket	NN	O
of	of	IN	O
FGFR1	fgfr1	CD	O
,	,	,	O
including	include	VBG	O
several	several	JJ	O
key	key	JJ	O
amino	amino	NN	O
acid	acid	NN	O
residues	residue	NNS	O
:	:	:	O
Glu562	glu562	CD	O
,	,	,	O
Ala564	ala564	CD	O
.	.	.	O

Compound	Compound	NNP	O
9d	9d	NNP	O
was	be	VBD	O
placed	place	VBN	O
during	during	IN	O
the	the	DT	O
molecular	molecular	JJ	O
docking	docking	NN	O
procedure	procedure	NN	O
.	.	.	O

Types	type	NNS	O
of	of	IN	O
interactions	interaction	NNS	O
of	of	IN	O
the	the	DT	O
docked	docked	JJ	O
protein	protein	NN	O
with	with	IN	O
ligand	ligand	NNP	O
were	be	VBD	O
analysed	analyse	VBN	O
after	after	IN	O
the	the	DT	O
end	end	NN	O
of	of	IN	O
molecular	molecular	JJ	O
docking	docking	NN	O
.	.	.	O

The	the	DT	O
detailed	detailed	JJ	O
structures	structure	NNS	O
and	and	CC	O
calculation	calculation	NN	O
results	result	NNS	O
were	be	VBD	O
shown	show	VBN	O
in	in	IN	O
Supplementary	Supplementary	NNP	O
Table	Table	NNP	O
S1	S1	NNS	O
.	.	.	O

Solvents	solvent	NNS	O
were	be	VBD	O
distilled	distil	VBN	O
under	under	IN	O
the	the	DT	O
positive	positive	JJ	O
pressure	pressure	NN	O
of	of	IN	O
dry	dry	JJ	O
argon	argon	NN	O
before	before	IN	O
use	use	NN	O
and	and	CC	O
dried	dry	VBD	O
using	use	VBG	O
standard	standard	JJ	O
methods	method	NNS	O
.	.	.	O

Chemicals	chemical	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
from	from	IN	O
local	local	JJ	O
suppliers	supplier	NNS	O
and	and	CC	O
were	be	VBD	O
used	use	VBN	O
without	without	IN	O
further	further	JJ	O
purification	purification	NN	O
.	.	.	O

All	all	DT	O
reactions	reaction	NNS	O
were	be	VBD	O
monitored	monitor	VBN	O
by	by	IN	O
thin	thin	JJ	O
-	-	HYPH	O
layer	layer	NN	O
chromatography	chromatography	NN	O
.	.	.	O

NMR	NMR	NNP	O
spectra	spectra	NNP	O
were	be	VBD	O
recorded	record	VBN	O
on	on	IN	O
Bruker	Bruker	NNP	O
400âMHz	400âmhz	CD	O
instruments	instrument	NNS	O
,	,	,	O
and	and	CC	O
the	the	DT	O
chemical	chemical	NN	O
shifts	shift	NNS	O
were	be	VBD	O
presented	present	VBN	O
in	in	IN	O
terms	term	NNS	O
of	of	IN	O
parts	part	NNS	O
per	per	IN	O
million	million	CD	O
with	with	IN	O
TMS	TMS	NNP	O
as	as	IN	O
the	the	DT	O
internal	internal	JJ	O
reference	reference	NN	O
.	.	.	O

Electron	Electron	NNP	O
-	-	HYPH	O
spray	spray	NNP	O
ionisation	ionisation	NN	O
mass	mass	NN	O
spectra	spectra	NNP	O
in	in	IN	O
positive	positive	JJ	O
mode	mode	NN	O
data	datum	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
with	with	IN	O
a	a	DT	O
Bruker	Bruker	NNP	O
Esquire	Esquire	NNP	O
3000	3000	CD	O
+	+	CC	O
spectrometer	spectrometer	NN	O
.	.	.	O

Flash	flash	NN	O
column	column	NN	O
chromatography	chromatography	NN	O
was	be	VBD	O
performed	perform	VBN	O
on	on	IN	O
silica	silica	NNP	O
gel	gel	NNP	O
200â300	200â300	CD	O
mesh	mesh	NN	O
,	,	,	O
Adamas	Adamas	NNP	O
,	,	,	O
China	China	NNP	O
.	.	.	O

The	the	DT	O
detail	detail	NN	O
experimental	experimental	JJ	O
procedures	procedure	NNS	O
of	of	IN	O
intermediate	intermediate	JJ	O
2	2	CD	O
,	,	,	O
3	3	CD	O
,	,	,	O
4	4	CD	O
,	,	,	O
6	6	CD	O
,	,	,	O
7	7	CD	O
and	and	CC	O
8	8	CD	O
are	be	VBP	O
described	describe	VBN	O
as	as	IN	O
previous	previous	JJ	O
reference	reference	NN	B
.	.	.	O

The	the	DT	O
kinase	kinase	NN	O
profiling	profiling	NN	O
of	of	IN	O
9âu	9âu	CD	O
was	be	VBD	O
conducted	conduct	VBN	O
using	use	VBG	O
Elisa	Elisa	NNP	O
kinase	kinase	NN	O
assay	assay	NN	O
and	and	CC	O
the	the	DT	O
Eurofins	Eurofins	NNP	O
Kinase	Kinase	NNP	O
Profiler	Profiler	NNP	O
Selectivity	Selectivity	NNP	O
Testing	Testing	NNP	O
Service	Service	NNP	O
.	.	.	O

Elisa	Elisa	NNP	O
kinase	kinase	VBD	O
assay	assay	NN	O
.	.	.	O

The	the	DT	O
effects	effect	NNS	O
of	of	IN	O
the	the	DT	O
indicated	indicate	VBN	O
compounds	compound	NNS	O
on	on	IN	O
the	the	DT	O
activities	activity	NNS	O
of	of	IN	O
receptor	receptor	NN	O
tyrosine	tyrosine	NN	O
kinases	kinase	NNS	O
were	be	VBD	O
determined	determine	VBN	O
using	use	VBG	O
enzyme	enzyme	NNS	O
-	-	HYPH	O
linked	link	VBN	O
immunosorbent	immunosorbent	NN	O
assays	assay	NNS	O
with	with	IN	O
purified	purify	VBN	O
recombinant	recombinant	JJ	O
proteins	protein	NNS	O
.	.	.	O

Briefly	briefly	RB	O
,	,	,	O
20âÎ¼g	20âî¼g	CD	O
/	/	SYM	O
mL	mL	NNP	O
poly	poly	NNP	O
4:1	4:1	CD	O
was	be	VBD	O
pre	pre	VBN	O
-	-	VBN	O
coated	coated	JJ	O
in	in	IN	O
96-well	96-well	CD	O
plates	plate	NNS	O
as	as	IN	O
a	a	DT	O
substrate	substrate	NN	O
.	.	.	O

A	a	DT	O
50âÎ¼L	50âî¼l	CD	O
aliquot	aliquot	NNS	O
of	of	IN	O
10âÎ¼mol	10âÎ¼mol	NNP	O
/	/	SYM	O
L	L	NNP	O
ATP	atp	NN	O
solution	solution	NN	O
diluted	dilute	VBN	O
in	in	IN	O
kinase	kinase	JJ	O
reaction	reaction	NN	O
buffer	buffer	NN	O
50âmmol	50âmmol	NNP	O
/	/	SYM	O
L	L	NNP	O
HEPES	HEPES	NNP	O
,	,	,	O
50âmmol	50âmmol	NNP	O
/	/	SYM	O
L	L	NNP	O
MgCl2	MgCl2	NNP	O
,	,	,	O
0.5âmmol	0.5âmmol	NNP	O
/	/	SYM	O
L	l	NN	O
MnCl2	mncl2	NN	O
,	,	,	O
0.2âmmol	0.2âmmol	NNP	O
/	/	SYM	O
L	L	NNP	O
Na3VO4	Na3VO4	NNP	O
,	,	,	O
and	and	CC	O
1âmmol	1âmmol	CD	O
/	/	SYM	O
L	L	NNP	O
DTT	DTT	NNP	O
was	be	VBD	O
added	add	VBN	O
to	to	IN	O
each	each	DT	O
well	well	RB	O
;	;	:	O
1âÎ¼L	1âî¼l	CD	O
of	of	IN	O
different	different	JJ	O
compounds	compound	NNS	O
with	with	IN	O
indicated	indicate	VBN	O
concentration	concentration	NN	O
diluted	dilute	VBN	O
in	in	IN	O
1	1	CD	O
%	%	NN	O
DMSO	DMSO	NNS	O
were	be	VBD	O
then	then	RB	O
added	add	VBN	O
to	to	IN	O
each	each	DT	O
reaction	reaction	NN	O
well	well	RB	O
.	.	.	O

DMSO	DMSO	NNP	O
was	be	VBD	O
used	use	VBN	O
as	as	IN	O
the	the	DT	O
negative	negative	JJ	O
control	control	NN	O
.	.	.	O

The	the	DT	O
kinase	kinase	NN	O
reaction	reaction	NN	O
was	be	VBD	O
initiated	initiate	VBN	O
by	by	IN	O
the	the	DT	O
addition	addition	NN	O
of	of	IN	O
purified	purify	VBN	O
tyrosine	tyrosine	JJ	O
kinase	kinase	NN	O
proteins	protein	NNS	O
diluted	dilute	VBN	O
in	in	IN	O
49âÎ¼L	49âî¼l	CD	O
of	of	IN	O
kinase	kinase	JJ	O
reaction	reaction	NN	O
buffer	buffer	NN	O
solution	solution	NN	O
.	.	.	O

After	after	IN	O
incubation	incubation	NN	O
for	for	IN	O
60âmin	60âmin	CD	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
the	the	DT	O
plate	plate	NN	O
was	be	VBD	O
washed	wash	VBN	O
three	three	CD	O
times	time	NNS	O
with	with	IN	O
phosphate	phosphate	NN	O
-	-	HYPH	O
buffered	buffer	VBN	O
saline	saline	NN	O
containing	contain	VBG	O
0.1	0.1	CD	O
%	%	NN	O
Tween	Tween	NNP	O
20	20	CD	O
.	.	.	O

Anti	anti	JJ	O
-	-	JJ	O
phosphotyrosine	phosphotyrosine	JJ	O
antibody	antibody	NN	O
100âÎ¼L	100âî¼l	CD	O
;	;	:	O
1:500	1:500	CD	O
,	,	,	O
diluted	dilute	VBN	O
in	in	IN	O
5âmg	5âmg	CD	O
/	/	SYM	O
mL	mL	NNP	O
BSA	BSA	NNP	O
T	T	NNP	O
-	-	HYPH	O
PBS	PBS	NNP	O
was	be	VBD	O
then	then	RB	O
added	add	VBN	O
.	.	.	O

After	after	IN	O
a	a	DT	O
30âmin	30âmin	NN	O
incubation	incubation	NN	O
at	at	IN	O
37âÂ	37âÂ	NNP	O
°	°	,	O
C	C	NNP	O
,	,	,	O
the	the	DT	O
plate	plate	NN	O
was	be	VBD	O
washed	wash	VBN	O
three	three	CD	O
times	time	NNS	O
,	,	,	O
and	and	CC	O
100âÎ¼L	100âî¼l	CD	O
horseradish	horseradish	NNP	O
peroxidase	peroxidase	NN	O
-	-	HYPH	O
conjugated	conjugate	VBN	O
goat	goat	NNP	O
anti	anti	JJ	O
-	-	JJ	O
mouse	mouse	JJ	O
IgG	IgG	NNP	O
1:2000	1:2000	CD	O
,	,	,	O
diluted	dilute	VBN	O
in	in	IN	O
5âmg	5âmg	CD	O
/	/	SYM	O
mL	mL	NNP	O
BSA	BSA	NNP	O
T	T	NNP	O
-	-	HYPH	O
PBS	PBS	NNP	O
was	be	VBD	O
added	add	VBN	O
.	.	.	O

The	the	DT	O
plate	plate	NN	O
was	be	VBD	O
then	then	RB	O
incubated	incubate	VBN	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
for	for	IN	O
30âmin	30âmin	NNP	O
and	and	CC	O
washed	wash	VBD	O
3	3	CD	O
times	time	NNS	O
.	.	.	O

A	a	DT	O
100âÎ¼L	100âî¼l	CD	O
aliquot	aliquot	NNS	O
of	of	IN	O
a	a	DT	O
solution	solution	NN	O
containing	contain	VBG	O
0.03	0.03	CD	O
%	%	NN	O
H2O2	H2O2	NNP	O
and	and	CC	O
2âmg	2âmg	CD	O
/	/	SYM	O
mL	mL	NNP	O
o	o	NN	O
-	-	HYPH	O
phenylenediamine	phenylenediamine	NN	O
in	in	IN	O
0.1âmol	0.1âmol	NNP	O
/	/	SYM	O
l	l	NNP	O
citrate	citrate	NN	O
buffer	buffer	NN	O
was	be	VBD	O
added	add	VBN	O
.	.	.	O

The	the	DT	O
reaction	reaction	NN	O
was	be	VBD	O
terminated	terminate	VBN	O
by	by	IN	O
the	the	DT	O
addition	addition	NN	O
of	of	IN	O
50âÎ¼L	50âî¼l	CD	O
of	of	IN	O
2âmol	2âmol	CD	O
/	/	SYM	O
l	l	NNP	O
H2SO4	H2SO4	NNP	O
as	as	IN	O
the	the	DT	O
colour	colour	NN	O
changed	change	VBD	O
,	,	,	O
and	and	CC	O
the	the	DT	O
plate	plate	NN	O
was	be	VBD	O
analysed	analyse	VBN	O
using	use	VBG	O
a	a	DT	O
multi	multi	JJ	O
-	-	JJ	O
well	well	RB	O
spectrophotometer	spectrophotometer	NN	O
at	at	IN	O
490ânm	490ânm	CD	O
.	.	.	O

The	the	DT	O
inhibition	inhibition	NN	O
rate	rate	NN	O
was	be	VBD	O
calculated	calculate	VBN	O
using	use	VBG	O
the	the	DT	O
following	following	JJ	O
equation	equation	NN	O
:	:	:	O
1-]âÃâ100	1-]âãâ100	CD	O
%	%	NN	O
.	.	.	O

The	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
from	from	IN	O
the	the	DT	O
inhibition	inhibition	NN	O
curves	curve	NNS	O
in	in	IN	O
two	two	CD	O
separate	separate	JJ	O
experiments	experiment	NNS	O
.	.	.	O

Human	human	JJ	O
gastric	gastric	JJ	O
cancer	cancer	NN	O
cell	cell	NN	O
line	line	NN	O
SNU-16	SNU-16	NNP	O
was	be	VBD	O
purchased	purchase	VBN	O
from	from	IN	O
American	American	NNP	O
Type	Type	NNP	O
Culture	Culture	NNP	O
Collection	Collection	NNP	O
.	.	.	O

All	all	PDT	O
the	the	DT	O
cell	cell	NN	O
lines	line	NNS	O
were	be	VBD	O
routinely	routinely	RB	O
maintained	maintain	VBN	O
in	in	IN	O
complete	complete	JJ	O
medium	medium	NN	O
according	accord	VBG	O
to	to	IN	O
the	the	DT	O
suppliersâ	suppliersâ	NNP	O
recommendations	recommendation	NNS	O
.	.	.	O

Cells	cell	NNS	O
were	be	VBD	O
seeded	seed	VBN	O
in	in	IN	O
96-well	96-well	CD	O
tissue	tissue	NN	O
culture	culture	NN	O
plates	plate	NNS	O
.	.	.	O

On	on	IN	O
the	the	DT	O
day	day	NN	O
when	when	WRB	O
seeding	seed	VBG	O
,	,	,	O
the	the	DT	O
cells	cell	NNS	O
were	be	VBD	O
exposed	expose	VBN	O
to	to	IN	O
various	various	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
compounds	compound	NNS	O
and	and	CC	O
further	further	RB	O
cultured	cultured	JJ	O
for	for	IN	O
72âh	72âh	CD	O
at	at	IN	O
37âÂ	37ââ	CD	O
°	°	,	O
C	C	NNP	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
cell	cell	NN	O
proliferation	proliferation	NN	O
was	be	VBD	O
determined	determine	VBN	O
using	use	VBG	O
Cell	Cell	NNP	O
Counting	Counting	NNP	O
Kit	Kit	NNP	O
or	or	CC	O
the	the	DT	O
thiazolyl	thiazolyl	JJ	O
blue	blue	JJ	O
tetrazolium	tetrazolium	NN	O
bromide	bromide	NN	O
assay	assay	NN	O
.	.	.	O

The	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
were	be	VBD	O
calculated	calculate	VBN	O
by	by	IN	O
concentrationâresponse	concentrationâresponse	NNP	O
curve	curve	NN	O
fitting	fitting	NN	O
using	use	VBG	O
a	a	DT	O
SoftMax	SoftMax	NNP	O
pro	pro	NN	O
-	-	HYPH	O
based	base	VBN	O
four	four	CD	O
-	-	HYPH	O
parameter	parameter	NN	O
method	method	NN	O
.	.	.	O

Most	Most	JJS	O
selective	selective	JJ	O
FGFR1	fgfr1	CD	O
inhibitors	inhibitor	NNS	O
are	be	VBP	O
ATP	atp	NN	O
-	-	HYPH	O
competitive	competitive	JJ	O
inhibitors	inhibitor	NNS	O
that	that	WDT	O
bind	bind	VBP	O
to	to	IN	O
the	the	DT	O
ATP	atp	NN	O
-	-	HYPH	O
binding	bind	VBG	O
pocket	pocket	NN	O
of	of	IN	O
FGFR	FGFR	NNP	O
.	.	.	O

The	the	DT	O
ATP	ATP	NNP	O
binding	bind	VBG	O
pocket	pocket	NN	O
of	of	IN	O
the	the	DT	O
FGFR1	FGFR1	NNS	O
consists	consist	VBZ	O
of	of	IN	O
five	five	CD	O
regions3	regions3	NN	O
,	,	,	B
,	,	,	B
:	:	:	O
the	the	DT	O
adenine	adenine	NN	O
region	region	NN	O
,	,	,	O
hydrophobic	hydrophobic	JJ	O
region	region	NN	O
I	-PRON-	PRP	O
,	,	,	O
hydrophobic	hydrophobic	JJ	O
region	region	NN	O
II	II	NNP	O
,	,	,	O
the	the	DT	O
nucleotide	nucleotide	JJ	O
domain	domain	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
phosphate	phosphate	NN	O
region	region	NN	O
.	.	.	O

The	the	DT	O
adenine	adenine	NN	O
region	region	NN	O
is	be	VBZ	O
considered	consider	VBN	O
as	as	IN	O
the	the	DT	O
major	major	JJ	O
binding	binding	NN	O
site	site	NN	O
in	in	IN	O
which	which	WDT	O
heterocycle	heterocycle	NN	O
scaffolds	scaffold	NNS	O
are	be	VBP	O
anchored	anchor	VBN	O
through	through	IN	O
several	several	JJ	O
H	h	NN	O
-	-	HYPH	O
bonds	bond	NNS	O
with	with	IN	O
a	a	DT	O
hinge	hinge	NN	O
region	region	NN	O
of	of	IN	O
the	the	DT	O
kinase	kinase	NN	O
.	.	.	O

Meanwhile	meanwhile	RB	O
,	,	,	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
region	region	NN	O
I	-PRON-	PRP	O
and	and	CC	O
hydrophobic	hydrophobic	JJ	O
region	region	NN	O
II	ii	CD	O
are	be	VBP	O
the	the	DT	O
other	other	JJ	O
two	two	CD	O
important	important	JJ	O
sites	site	NNS	O
,	,	,	O
which	which	WDT	O
plays	play	VBZ	O
key	key	JJ	O
factor	factor	NN	O
in	in	IN	O
binding	bind	VBG	O
small	small	JJ	O
molecules	molecule	NNS	O
by	by	IN	O
interacting	interact	VBG	O
with	with	IN	O
lipophilic	lipophilic	JJ	O
moieties	moiety	NNS	O
hydrophobically	hydrophobically	RB	O
,	,	,	O
and	and	CC	O
forms	form	NNS	O
van	van	NNP	O
der	der	NNP	O
Waals	Waals	NNP	O
interactions	interaction	NNS	O
and	and	CC	O
H	h	NN	O
-	-	HYPH	O
bonds	bond	NNS	O
.	.	.	O

Accordingly	accordingly	RB	O
,	,	,	O
the	the	DT	O
inhibitors	inhibitor	NNS	O
are	be	VBP	O
commonly	commonly	RB	O
involving	involve	VBG	O
the	the	DT	O
following	follow	VBG	O
pharmacophore	pharmacophore	NN	O
features	feature	NNS	O
.	.	.	O

The	the	DT	O
core	core	JJ	O
structure	structure	NN	O
of	of	IN	O
most	most	JJS	O
inhibitors	inhibitor	NNS	O
consists	consist	VBZ	O
of	of	IN	O
a	a	DT	O
flat	flat	JJ	O
hetero	hetero	NNP	O
aromatic	aromatic	JJ	O
ring	ring	NN	O
system	system	NN	O
that	that	WDT	O
contains	contain	VBZ	O
at	at	IN	O
least	least	JJS	O
one	one	CD	O
H	h	NN	O
-	-	HYPH	O
bond	bond	NN	O
acceptor	acceptor	NN	O
and	and	CC	O
H	h	NN	O
-	-	HYPH	O
bond	bond	NN	O
donor	donor	NN	O
,	,	,	O
then	then	RB	O
it	-PRON-	PRP	O
can	can	MD	O
form	form	VB	O
hydrogen	hydrogen	NN	O
bonds	bond	NNS	O
with	with	IN	O
the	the	DT	O
key	key	JJ	O
amino	amino	NN	O
acid	acid	NN	O
residues	residue	NNS	O
:	:	:	O
Glu562	glu562	CD	O
and	and	CC	O
Ala564	ala564	CD	O
.	.	.	O

Terminal	terminal	JJ	O
hydrophobic	hydrophobic	JJ	O
head	head	NN	O
often	often	RB	O
interacts	interact	VBZ	O
with	with	IN	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
region	region	NN	O
I	I	NNP	O
,	,	,	O
which	which	WDT	O
is	be	VBZ	O
a	a	DT	O
phenyl	phenyl	NN	O
ring	ring	NN	O
with	with	IN	O
different	different	JJ	O
extra	extra	JJ	O
hydrophobic	hydrophobic	JJ	O
substitutions	substitution	NNS	O
.	.	.	O

Another	another	DT	O
hydrophobic	hydrophobic	NN	O
scaffold	scaffold	NN	O
directly	directly	RB	O
linked	link	VBN	O
to	to	IN	O
the	the	DT	O
flat	flat	JJ	O
hetero	hetero	NNP	O
aromatic	aromatic	NNP	O
ring	ring	NN	O
system	system	NN	O
which	which	WDT	O
occupies	occupy	VBZ	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
region	region	NN	O
II	II	NNP	O
.	.	.	O

Herein	Herein	NNP	O
,	,	,	O
we	-PRON-	PRP	O
initially	initially	RB	O
pay	pay	VBP	O
attention	attention	NN	O
to	to	TO	O
explore	explore	VB	O
the	the	DT	O
novel	novel	JJ	O
hetero	hetero	NNP	O
aromatic	aromatic	NNP	O
ring	ring	NN	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
the	the	DT	O
core	core	JJ	O
structure	structure	NN	O
of	of	IN	O
FGFR1	fgfr1	JJ	O
inhibitor	inhibitor	NN	O
,	,	,	O
formed	form	VBD	O
the	the	DT	O
key	key	JJ	O
H	h	NN	O
-	-	HYPH	O
bond	bond	NN	O
interaction	interaction	NN	O
with	with	IN	O
hinge	hinge	NN	O
region	region	NN	O
,	,	,	O
and	and	CC	O
connected	connect	VBD	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
region	region	NN	O
I	-PRON-	PRP	O
and	and	CC	O
II	II	NNP	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
we	-PRON-	PRP	O
superimposed	superimpose	VBD	O
the	the	DT	O
two	two	CD	O
FGFR1	FGFR1	NNP	O
crystal	crystal	NN	O
structures	structure	NNS	O
of	of	IN	O
4V05	4v05	CD	O
and	and	CC	O
3TTO	3TTO	NNP	O
,	,	,	O
which	which	WDT	O
were	be	VBD	O
complexed	complexe	VBN	O
with	with	IN	O
AZD4547	AZD4547	NNP	B
and	and	CC	O
NVP	NVP	NNP	O
-	-	HYPH	O
BGJ	BGJ	NNP	O
398	398	CD	B
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
revealed	reveal	VBD	O
that	that	IN	O
AZD4547	AZD4547	NNP	O
and	and	CC	O
NVP	NVP	NNP	O
-	-	HYPH	O
BGJ	BGJ	NNP	O
398	398	CD	O
were	be	VBD	O
similar	similar	JJ	O
in	in	IN	O
their	-PRON-	PRP$	O
binding	binding	JJ	O
mode	mode	NN	O
with	with	IN	O
the	the	DT	O
target	target	NN	O
were	be	VBD	O
similarly	similarly	RB	O
,	,	,	O
when	when	WRB	O
there	there	EX	O
was	be	VBD	O
a	a	DT	O
significant	significant	JJ	O
spatial	spatial	JJ	O
distance	distance	NN	O
constraint	constraint	NN	O
between	between	IN	O
the	the	DT	O
pharmacophore	pharmacophore	NN	O
features	feature	NNS	O
.	.	.	O

The	the	DT	O
spatial	spatial	JJ	O
distance	distance	NN	O
of	of	IN	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
head	head	NN	O
and	and	CC	O
the	the	DT	O
heterocycle	heterocycle	NN	O
ring	ring	NN	O
is	be	VBZ	O
between	between	IN	O
5.9âÃ	5.9âã	CD	O
and	and	CC	O
6.5âÃ	6.5âã	CD	O
Figure	Figure	NNP	O
2and	2and	CD	O
Figure	Figure	NNP	O
S2	s2	NN	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
the	the	DT	O
FGFR1	fgfr1	CD	O
inhibitors	inhibitor	NNS	O
might	may	MD	O
contain	contain	VB	O
the	the	DT	O
corresponding	correspond	VBG	O
pharmacophore	pharmacophore	NN	O
features	feature	NNS	O
,	,	,	O
and	and	CC	O
these	these	DT	O
pharmacophore	pharmacophore	NN	O
features	feature	NNS	O
were	be	VBD	O
also	also	RB	O
consisted	consist	VBN	O
to	to	IN	O
a	a	DT	O
space	space	NN	O
distance	distance	NN	O
constraint	constraint	NN	O
.	.	.	O

The	the	DT	O
fragment	fragment	NN	O
library	library	NN	O
was	be	VBD	O
derived	derive	VBN	O
from	from	IN	O
kinase	kinase	NNP	O
hinge	hinge	NN	O
region	region	NN	O
directed	direct	VBN	O
library	library	NN	O
,	,	,	O
which	which	WDT	O
contained	contain	VBD	O
11809	11809	CD	O
scaffolds	scaffold	NNS	O
.	.	.	O

Subsequently	subsequently	RB	O
,	,	,	O
with	with	IN	O
the	the	DT	O
built	build	VBN	O
pharmacophore	pharmacophore	NN	O
model	model	NN	O
and	and	CC	O
molecular	molecular	JJ	O
docking	docking	NN	O
,	,	,	O
seven	seven	CD	O
hit	hit	NN	O
fragments	fragment	NNS	O
were	be	VBD	O
obtained	obtain	VBN	O
through	through	IN	O
serval	serval	JJ	O
round	round	JJ	O
filtration	filtration	NN	O
.	.	.	O

One	one	CD	O
of	of	IN	O
them	-PRON-	PRP	O
was	be	VBD	O
indazole	indazole	NN	O
scaffold	scaffold	JJ	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
proved	prove	VBN	O
to	to	TO	O
be	be	VB	O
an	an	DT	O
efficiency	efficiency	NN	O
FGFR1	fgfr1	NN	O
inhibitor	inhibitor	NN	O
scaffold	scaffold	JJ	B
,	,	,	O
which	which	WDT	O
indicated	indicate	VBD	O
the	the	DT	O
accuracy	accuracy	NN	O
of	of	IN	O
virtual	virtual	JJ	O
screening	screening	NN	O
protocol	protocol	NN	O
.	.	.	O

Then	then	RB	O
,	,	,	O
in	in	IN	O
view	view	NN	O
of	of	IN	O
the	the	DT	O
difficulties	difficulty	NNS	O
in	in	IN	O
synthesis	synthesis	NN	O
,	,	,	O
only	only	RB	O
1H-1,2,4-triazole	1h-1,2,4-triazole	CD	O
,	,	,	O
benzothiazole	benzothiazole	NN	O
and	and	CC	O
indazole	indazole	NNP	O
scaffold	scaffold	NNP	O
were	be	VBD	O
selected	select	VBN	O
for	for	IN	O
further	further	JJ	O
modification	modification	NN	O
Figure	Figure	NNP	O
2	2	CD	O
.	.	.	O

The	the	DT	O
novel	novel	JJ	O
1H-1,2,4-triazole	1h-1,2,4-triazole	CD	O
and	and	CC	O
benzothiazole	benzothiazole	NN	O
scaffolds	scaffold	NNS	O
were	be	VBD	O
selected	select	VBN	O
for	for	IN	O
the	the	DT	O
study	study	NN	O
of	of	IN	O
FGFR1	FGFR1	NNP	O
inhibitors	inhibitor	NNS	O
research	research	NN	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
we	-PRON-	PRP	O
also	also	RB	O
continued	continue	VBD	O
to	to	TO	O
optimise	optimise	VB	O
the	the	DT	O
original	original	JJ	O
indazole	indazole	NN	O
derivatives	derivative	NNS	O
,	,	,	O
improve	improve	VB	O
the	the	DT	O
physicochemical	physicochemical	JJ	O
property	property	NN	O
and	and	CC	O
enrich	enrich	VB	O
the	the	DT	O
structure	structure	NN	O
-	-	HYPH	O
activity	activity	NN	O
relationship	relationship	NN	O
of	of	IN	O
indazole	indazole	NN	O
derivatives	derivative	NNS	O
.	.	.	O

Finally	finally	RB	O
,	,	,	O
we	-PRON-	PRP	O
synthesised	synthesise	VBD	O
several	several	JJ	O
indazole	indazole	NN	O
derivatives	derivative	NNS	O
through	through	IN	O
introduced	introduce	VBN	O
halogen	halogen	NN	O
substituents	substituent	NNS	O
at	at	IN	O
various	various	JJ	O
positions	position	NNS	O
.	.	.	O

As	as	IN	O
a	a	DT	O
result	result	NN	O
,	,	,	O
with	with	IN	O
the	the	DT	O
fragment	fragment	NN	O
-	-	HYPH	O
based	base	VBN	O
virtual	virtual	JJ	O
screening	screening	NN	O
strategy	strategy	NN	O
,	,	,	O
novel	novel	JJ	O
derivatives	derivative	NNS	O
bearing	bear	VBG	O
1H-1,2,4-triazole	1h-1,2,4-triazole	CD	O
,	,	,	O
benzothiazole	benzothiazole	NNP	O
and	and	CC	O
indazole	indazole	NN	O
scaffold	scaffold	NNP	O
were	be	VBD	O
designed	design	VBN	O
,	,	,	O
synthesised	synthesise	VBN	O
and	and	CC	O
evaluated	evaluate	VBN	O
.	.	.	O

The	the	DT	O
preparation	preparation	NN	O
of	of	IN	O
target	target	NN	O
compounds	compound	NNS	O
9a	9a	NNP	O
-	-	HYPH	O
t	t	NN	O
,	,	,	O
12a	12a	NNS	O
-	-	HYPH	O
d	d	NNS	O
and	and	CC	O
18a	18a	NNS	O
-	-	:	O
c	c	NNP	O
was	be	VBD	O
described	describe	VBN	O
in	in	IN	O
Schemes	Schemes	NNP	O
1â3	1â3	NNP	O
.	.	.	O

Compounds	compound	VBZ	O
9a	9a	NNP	O
-	-	HYPH	O
t	t	NNP	O
were	be	VBD	O
synthesised	synthesise	VBN	O
from	from	IN	O
starting	start	VBG	O
material	material	NN	O
4-fluorobenzoate	4-fluorobenzoate	CD	O
and	and	CC	O
4-bromo-2-fluorobenzonitrile	4-bromo-2-fluorobenzonitrile	CD	O
through	through	IN	O
seven	seven	CD	O
steps	step	NNS	O
.	.	.	O

The	the	DT	O
nucleophilic	nucleophilic	JJ	O
substitution	substitution	NN	O
reactions	reaction	NNS	O
of	of	IN	O
4-fluorobenzoate	4-fluorobenzoate	CD	O
with	with	IN	O
various	various	JJ	O
piperazines	piperazine	NNS	O
afforded	afford	VBD	O
the	the	DT	O
methyl	methyl	NN	O
ester	ester	NN	O
2	2	CD	O
intermediate	intermediate	JJ	O
,	,	,	O
which	which	WDT	O
then	then	RB	O
could	could	MD	O
hydrolysis	hydrolysis	VB	O
to	to	IN	O
carboxylic	carboxylic	JJ	O
acid	acid	NN	O
3	3	CD	O
.	.	.	O

Subsequently	subsequently	RB	O
,	,	,	O
the	the	DT	O
carboxylic	carboxylic	JJ	O
acid	acid	NN	O
3	3	CD	O
was	be	VBD	O
condensed	condense	VBN	O
with	with	IN	O
HATU	HATU	NNP	O
to	to	TO	O
provide	provide	VB	O
the	the	DT	O
activated	activate	VBN	O
ester	ester	NN	O
reagent	reagent	NNP	O
4	4	CD	O
.	.	.	O

Meanwhile	meanwhile	RB	O
,	,	,	O
the	the	DT	O
intermediate	intermediate	JJ	O
5	5	CD	O
could	could	MD	O
be	be	VB	O
condensed	condense	VBN	O
by	by	IN	O
4-bromo-2-fluorobenzonitrile	4-bromo-2-fluorobenzonitrile	CD	O
1	1	CD	O
with	with	IN	O
hydrazine	hydrazine	NN	O
.	.	.	O

Then	then	RB	O
nitrogen	nitrogen	VB	O
atom	atom	NN	O
at	at	IN	O
the	the	DT	O
1-position	1-position	CD	O
of	of	IN	O
1H	1h	CD	O
-	-	HYPH	O
indazol-3-amine	indazol-3-amine	NNP	O
scaffold	scaffold	NN	O
5	5	CD	O
was	be	VBD	O
protected	protect	VBN	O
by	by	IN	O
BOC	BOC	NNP	O
group	group	NN	O
.	.	.	O

The	the	DT	O
key	key	JJ	O
intermediate	intermediate	NN	O
8	8	CD	O
was	be	VBD	O
obtained	obtain	VBN	O
by	by	IN	O
condensation	condensation	NN	O
of	of	IN	O
4	4	CD	O
and	and	CC	O
7	7	CD	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
NaH.	NaH.	NNP	O
Treatment	Treatment	NNP	O
of	of	IN	O
the	the	DT	O
intermediate	intermediate	JJ	O
8	8	CD	O
with	with	IN	O
various	various	JJ	O
substituted	substitute	VBN	O
-	-	HYPH	O
phenylboronic	phenylboronic	JJ	O
acid	acid	NN	O
under	under	IN	O
Suzuki	Suzuki	NNP	O
coupling	couple	VBG	O
condition	condition	NN	B
of	of	IN	O
PdCl2	PdCl2	NNPS	O
and	and	CC	O
Cs2CO3	Cs2CO3	NNP	O
in	in	IN	O
refluxing	refluxe	VBG	O
dioxane	dioxane	NN	O
/	/	SYM	O
water	water	NN	O
gave	give	VBD	O
target	target	NN	O
compounds	compound	NNS	O
.	.	.	O

According	accord	VBG	O
to	to	IN	O
the	the	DT	O
similar	similar	JJ	O
synthetic	synthetic	JJ	O
route	route	NN	O
,	,	,	O
compounds	compound	VBZ	O
12a	12a	NNS	O
-	-	HYPH	O
d	d	NNPS	O
were	be	VBD	O
synthesised	synthesise	VBN	O
from	from	IN	O
the	the	DT	O
starting	start	VBG	O
material	material	NN	O
6-bromobenzothiazol-2-amine	6-bromobenzothiazol-2-amine	CD	O
through	through	IN	O
two	two	CD	O
steps	step	NNS	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
indazole	indazole	NN	O
derivatives	derivative	NNS	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
K2CO3	K2CO3	NNP	O
,	,	,	O
DMSO	DMSO	NNP	O
,	,	,	O
120âÂ	120ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
85â90	85â90	CD	O
%	%	NN	O
;	;	:	O
NaOH	NaOH	NNP	O
,	,	,	O
MeOH	MeOH	NNP	O
,	,	,	O
H2O	h2o	NN	O
,	,	,	O
80âÂ	80âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
,	,	,	O
93â96	93â96	CD	O
%	%	NN	O
;	;	:	O
HATU	HATU	NNP	O
,	,	,	O
K2CO3	K2CO3	NNP	O
,	,	,	O
DMF	DMF	NNP	O
,	,	,	O
rt	rt	NNP	O
,	,	,	O
62â70	62â70	CD	O
%	%	NN	O
;	;	,	O
hydrazine	hydrazine	NNP	O
hydrate	hydrate	NN	O
,	,	,	O
n	n	JJ	O
-	-	HYPH	O
butanol	butanol	NN	O
,	,	,	O
120âÂ	120ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
86	86	CD	O
%	%	NN	O
;	;	,	O
Boc2O	Boc2O	NNS	O
,	,	,	O
DMAP	dmap	NN	O
,	,	,	O
THF	THF	NNP	O
,	,	,	O
89	89	CD	O
%	%	NN	O
;	;	,	O
NaH	NaH	NNP	O
,	,	,	O
THF	THF	NNP	O
,	,	,	O
60âÂ	60âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
,	,	,	O
52â61	52â61	CD	O
%	%	NN	O
;	;	:	O
TFA	TFA	NNP	O
,	,	,	O
CH2Cl2	CH2Cl2	NNP	O
,	,	,	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
70	70	CD	O
%	%	NN	O
;	;	:	O
R	R	NNP	O
-	-	HYPH	O
B2	B2	NNP	O
,	,	,	O
Cs2CO3	Cs2CO3	NNP	O
,	,	,	O
PdCl2	PdCl2	NNPS	O
,	,	,	O
dioxane	dioxane	NN	O
,	,	,	O
120âÂ	120ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
30â48	30â48	CD	O
%	%	NN	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
benzothiazole	benzothiazole	NN	O
derivatives	derivative	NNS	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
4	4	CD	O
,	,	,	O
NaH	NaH	NNP	O
,	,	,	O
THF	THF	NNP	O
,	,	,	O
60âÂ	60âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
,	,	,	O
51â62	51â62	CD	O
%	%	NN	O
;	;	:	O
R	R	NNP	O
-	-	HYPH	O
B2	B2	NNP	O
,	,	,	O
Cs2CO3	Cs2CO3	NNP	O
,	,	,	O
PdCl2	PdCl2	NNPS	O
,	,	,	O
dioxane	dioxane	NN	O
,	,	,	O
120âÂ	120ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
47â53	47â53	CD	O
%	%	NN	O
.	.	.	O

Synthesis	synthesis	NN	O
of	of	IN	O
1H-1,2,4-triazole	1h-1,2,4-triazole	CD	O
derivatives	derivative	NNS	O
.	.	.	O

Reagents	reagent	NNS	O
and	and	CC	O
conditions	condition	NNS	O
:	:	:	O
propanedioic	propanedioic	NNP	O
acid	acid	NNP	O
,	,	,	O
pyridine	pyridine	NNP	O
,	,	,	O
piperidine	piperidine	NN	O
,	,	,	O
105âÂ	105ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
77â82	77â82	CD	O
%	%	NN	O
;	;	:	O
Pd	Pd	NNP	O
/	/	SYM	O
C	C	NNP	O
,	,	,	O
H2	H2	NNP	O
,	,	,	O
EtOH	EtOH	NNP	O
,	,	,	O
88â93	88â93	CD	O
%	%	NN	O
;	;	:	O
SO2Cl2	SO2Cl2	NNP	O
,	,	,	O
reflux	reflux	NN	O
;	;	,	O
amino	amino	NNP	O
guanidine	guanidine	NNP	O
hydrochloride	hydrochloride	NNP	O
,	,	,	O
140âÂ	140ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
49â53	49â53	CD	O
%	%	NN	O
;	;	:	O
4	4	CD	O
,	,	,	O
NaH	NaH	NNP	O
,	,	,	O
THF	THF	NNP	O
,	,	,	O
60âÂ	60âÂ	NNP	O
°	°	NNP	O
C	C	NNP	O
,	,	,	O
54â62	54â62	CD	O
%	%	NN	O
;	;	:	O
TFA	TFA	NNP	O
,	,	,	O
CH2Cl2	CH2Cl2	NNP	O
,	,	,	O
0âÂ	0ââ	CD	O
°	°	,	O
C	C	NNP	O
,	,	,	O
70	70	CD	O
%	%	NN	O
.	.	.	O

The	the	DT	O
synthesis	synthesis	NN	O
of	of	IN	O
the	the	DT	O
other	other	JJ	O
1H-1,2,4-triazole	1h-1,2,4-triazole	CD	O
derivatives	derivative	NNS	O
was	be	VBD	O
shown	show	VBN	O
in	in	IN	O
Scheme	Scheme	NNP	O
3	3	CD	O
.	.	.	O

The	the	DT	O
starting	start	VBG	O
material	material	NN	O
substituted	substitute	VBN	O
-	-	HYPH	O
benzaldehyde	benzaldehyde	NNP	O
was	be	VBD	O
condensed	condense	VBN	O
with	with	IN	O
propanedioic	propanedioic	JJ	O
acid	acid	NN	O
in	in	IN	O
the	the	DT	O
presence	presence	NN	O
of	of	IN	O
pyridine	pyridine	NNP	O
and	and	CC	O
piperidine	piperidine	NNP	O
at	at	IN	O
105âÂ	105ââ	CD	O
°	°	,	O
C	C	NNP	O
via	via	IN	O
Aldol	Aldol	NNP	O
condensation	condensation	NN	O
,	,	,	O
which	which	WDT	O
the	the	DT	O
intermediate	intermediate	JJ	O
14	14	CD	O
was	be	VBD	O
obtained	obtain	VBN	O
.	.	.	O

After	after	IN	O
hydrogenation	hydrogenation	NN	O
of	of	IN	O
14	14	CD	O
released	release	VBD	O
the	the	DT	O
corresponding	corresponding	JJ	O
aliphatic	aliphatic	JJ	O
acid	acid	NN	O
15	15	CD	O
,	,	,	O
which	which	WDT	O
was	be	VBD	O
connected	connect	VBN	O
with	with	IN	O
the	the	DT	O
amino	amino	NNP	O
guanidine	guanidine	NN	O
hydrochloride	hydrochloride	NNP	O
giving	give	VBG	O
triazole	triazole	NNP	O
scaffold	scaffold	NNP	O
16	16	CD	O
in	in	IN	O
49.1	49.1	CD	O
%	%	NN	O
yield	yield	NN	O
.	.	.	O

Then	then	RB	O
nitrogen	nitrogen	VB	O
atom	atom	NN	O
at	at	IN	O
the	the	DT	O
1-position	1-position	CD	O
of	of	IN	O
the	the	DT	O
1H-1,2,4-triazole	1h-1,2,4-triazole	CD	O
heterocycle	heterocycle	NNP	O
16	16	CD	O
was	be	VBD	O
protected	protect	VBN	O
by	by	IN	O
BOC	BOC	NNP	O
group	group	NN	O
.	.	.	O

The	the	DT	O
target	target	NN	O
compounds	compound	VBZ	O
18a	18a	NNS	O
-	-	:	O
c	c	NNPS	O
were	be	VBD	O
prepared	prepare	VBN	O
in	in	IN	O
similar	similar	JJ	O
way	way	NN	O
by	by	IN	O
following	follow	VBG	O
condensation	condensation	NN	O
and	and	CC	O
Suzuki	Suzuki	NNP	O
-	-	HYPH	O
coupling	couple	VBG	O
procedures	procedure	NNS	O
.	.	.	O

Initially	initially	RB	O
,	,	,	O
we	-PRON-	PRP	O
designed	design	VBD	O
and	and	CC	O
synthesised	synthesise	VBD	O
the	the	DT	O
indazole	indazole	NN	O
,	,	,	O
benzothiazole	benzothiazole	NN	O
and	and	CC	O
1H-1,2,4-triazole	1h-1,2,4-triazole	CD	O
derivatives	derivative	NNS	O
,	,	,	O
with	with	IN	O
the	the	DT	O
goal	goal	NN	O
of	of	IN	O
analysing	analyse	VBG	O
the	the	DT	O
effects	effect	NNS	O
of	of	IN	O
different	different	JJ	O
scaffolds	scaffold	NNS	O
on	on	IN	O
biological	biological	JJ	O
activity	activity	NN	O
.	.	.	O

All	all	PDT	O
these	these	DT	O
compounds	compound	NNS	O
were	be	VBD	O
evaluated	evaluate	VBN	O
against	against	IN	O
FGFR1	FGFR1	NNP	O
enzyme	enzyme	NNS	O
and	and	CC	O
SNU-16	snu-16	JJ	O
cell	cell	NN	O
line	line	NN	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
indicated	indicate	VBD	O
that	that	IN	O
when	when	WRB	O
the	the	DT	O
heterocycle	heterocycle	NN	O
was	be	VBD	O
substituted	substitute	VBN	O
by	by	IN	O
a	a	DT	O
1H-1,2,4-triazole	1h-1,2,4-triazole	CD	O
scaffold	scaffold	NN	O
,	,	,	O
it	-PRON-	PRP	O
would	would	MD	O
result	result	VB	O
in	in	IN	O
almost	almost	RB	O
no	no	DT	O
enzyme	enzyme	NNS	O
inhibitory	inhibitory	VBP	O
activities	activity	NNS	O
and	and	CC	O
cell	cell	NN	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activities	activity	NNS	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
the	the	DT	O
corresponding	corresponding	JJ	O
benzothiazole	benzothiazole	NN	O
derivatives	derivative	NNS	O
12a	12a	NNS	O
-	-	HYPH	O
d	d	NNPS	O
were	be	VBD	O
also	also	RB	O
revealed	reveal	VBN	O
poor	poor	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
FGFR1	fgfr1	CD	O
enzyme	enzyme	NNS	O
IC50	IC50	NNP	O
>	>	XX	O
1000ânM	1000ânm	CD	O
,	,	,	O
thus	thus	RB	O
led	lead	VBD	O
to	to	IN	O
slight	slight	JJ	O
reduction	reduction	NN	O
cellular	cellular	JJ	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activities	activity	NNS	O
.	.	.	O

Structures	structure	NNS	O
and	and	CC	O
activities	activity	NNS	O
of	of	IN	O
various	various	JJ	O
derivatives	derivative	NNS	O
9a	9a	NNP	O
-	-	HYPH	O
d	d	NN	O
,	,	,	O
12a	12a	NNS	O
-	-	HYPH	O
d	d	NN	O
,	,	,	O
and	and	CC	O
18a	18a	NNS	O
-	-	:	O
c	c	NN	O
.	.	.	O

The	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
are	be	VBP	O
shown	show	VBN	O
as	as	IN	O
the	the	DT	O
average	average	JJ	O
values	value	NNS	O
from	from	IN	O
two	two	CD	O
separate	separate	JJ	O
experiments	experiment	NNS	O
.	.	.	O

SNU-16	snu-16	CD	O
is	be	VBZ	O
FGFR2-amplified	FGFR2-amplified	NNP	O
cell	cell	NN	O
type	type	NN	O
.	.	.	O

âNAâ	âNAâ	NFP	O
means	mean	VBZ	O
IC50	IC50	NNP	O
>	>	XX	O
5âÎ¼M.	5âÎ¼M.	NNP	O
Fortunately	fortunately	RB	O
,	,	,	O
compound	compound	VB	O
9a	9a	NN	O
with	with	IN	O
an	an	DT	O
indazole	indazole	NN	O
scaffold	scaffold	NN	O
exhibited	exhibit	VBD	O
good	good	JJ	O
FGFR1	fgfr1	NN	O
enzyme	enzyme	NNS	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
IC50	IC50	NNP	O
=	=	SYM	O
30.6ânM	30.6ânM	NNP	O
and	and	CC	O
modest	modest	JJ	O
cellular	cellular	JJ	O
inhibition	inhibition	NN	O
IC50	IC50	NNP	O
=	=	SYM	O
1195.7ânM	1195.7ânm	CD	O
.	.	.	O

While	while	IN	O
the	the	DT	O
3,5-dimethoxy	3,5-dimethoxy	JJ	O
phenyl	phenyl	NN	O
substituent	substituent	NN	O
was	be	VBD	O
replaced	replace	VBN	O
with	with	IN	O
the	the	DT	O
3-methoxy	3-methoxy	CD	O
phenyl	phenyl	NNP	O
group	group	NN	O
,	,	,	O
the	the	DT	O
enzyme	enzyme	NNS	O
inhibition	inhibition	NN	O
of	of	IN	O
9âb	9âb	CD	O
was	be	VBD	O
relatively	relatively	RB	O
lower	low	JJR	O
than	than	IN	O
9a	9a	NN	O
.	.	.	O

However	however	RB	O
it	-PRON-	PRP	O
was	be	VBD	O
more	more	RBR	O
potent	potent	JJ	O
in	in	IN	O
cellular	cellular	JJ	O
assay	assay	NN	O
9a	9a	NN	O
vs	vs	IN	O
9âb	9âb	CD	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
co	co	JJ	O
-	-	JJ	O
crystal	crystal	JJ	O
structure	structure	NN	O
analysis	analysis	NN	O
revealed	reveal	VBD	O
that	that	IN	O
the	the	DT	O
R1	r1	JJ	O
substituent	substituent	NN	O
is	be	VBZ	O
at	at	IN	O
the	the	DT	O
solvent	solvent	NN	O
region	region	NN	O
of	of	IN	O
the	the	DT	O
target	target	NN	O
protein	protein	NN	O
,	,	,	O
which	which	WDT	O
might	may	MD	O
be	be	VB	O
helpful	helpful	JJ	O
to	to	TO	O
improve	improve	VB	O
membrane	membrane	NN	O
permeability	permeability	NN	O
and	and	CC	O
enhance	enhance	VB	O
cellular	cellular	JJ	O
potencies	potency	NNS	O
.	.	.	O

Then	then	RB	O
the	the	DT	O
other	other	JJ	O
two	two	CD	O
derivatives	derivative	NNS	O
9c	9c	JJ	O
and	and	CC	O
9d	9d	NN	O
with	with	IN	O
N	N	NNP	O
-	-	HYPH	O
methyl	methyl	NN	O
piperazine	piperazine	NN	O
and	and	CC	O
N	N	NNP	O
-	-	HYPH	O
ethyl	ethyl	NN	O
piperazine	piperazine	NN	O
substituent	substituent	NN	O
at	at	IN	O
the	the	DT	O
R1	r1	JJ	O
position	position	NN	O
,	,	,	O
respectively	respectively	RB	O
,	,	,	O
were	be	VBD	O
synthesised	synthesise	VBN	O
and	and	CC	O
evaluated	evaluate	VBN	O
.	.	.	O

As	as	IN	O
a	a	DT	O
result	result	NN	O
,	,	,	O
the	the	DT	O
9d	9d	NN	O
demonstrated	demonstrate	VBD	O
the	the	DT	O
best	good	JJS	O
enzyme	enzyme	NNS	O
inhibitory	inhibitory	NN	O
IC50	IC50	NNP	O
=	=	SYM	O
15.0ânM	15.0ânm	CD	O
and	and	CC	O
cellular	cellular	JJ	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activities	activity	NNS	O
IC50	IC50	NNP	O
=	=	SYM	O
785.8ânM	785.8ânm	CD	O
.	.	.	O

The	the	DT	O
above	above	JJ	O
results	result	NNS	O
demonstrated	demonstrate	VBD	O
that	that	IN	O
the	the	DT	O
heterocycle	heterocycle	NN	O
could	could	MD	O
significantly	significantly	RB	O
affect	affect	VB	O
the	the	DT	O
enzyme	enzyme	NNS	O
and	and	CC	O
cell	cell	NN	O
growth	growth	NN	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
.	.	.	O

The	the	DT	O
hydrophobic	hydrophobic	JJ	O
group	group	NN	O
I	-PRON-	PRP	O
located	locate	VBD	O
in	in	IN	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
cavity	cavity	NN	O
of	of	IN	O
the	the	DT	O
active	active	JJ	O
site	site	NN	O
and	and	CC	O
formed	form	VBD	O
strong	strong	JJ	O
hydrophobic	hydrophobic	JJ	O
interaction	interaction	NN	O
with	with	IN	O
the	the	DT	O
target	target	NN	O
.	.	.	O

To	to	TO	O
increase	increase	VB	O
the	the	DT	O
enzyme	enzyme	NNS	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
,	,	,	O
we	-PRON-	PRP	O
initially	initially	RB	O
optimised	optimise	VBD	O
the	the	DT	O
hydrophobic	hydrophobic	NN	O
group	group	NN	O
I	-PRON-	PRP	O
.	.	.	O

It	-PRON-	PRP	O
was	be	VBD	O
indicated	indicate	VBN	O
that	that	IN	O
3-methoxy	3-methoxy	CD	O
phenyl	phenyl	NN	O
9d	9d	NN	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
15.0ânM	15.0ânM	NNP	O
was	be	VBD	O
substituted	substitute	VBN	O
by	by	IN	O
the	the	DT	O
3-ethoxy	3-ethoxy	CD	O
phenyl	phenyl	NN	O
9e	9e	NN	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
13.2ânM	13.2ânM	NNP	O
,	,	,	O
3-isopropoxy	3-isopropoxy	CD	O
phenyl	phenyl	NN	O
9f	9f	CD	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
9.8ânM	9.8ânM	NNP	O
caused	cause	VBD	O
increase	increase	NN	O
of	of	IN	O
activity	activity	NN	O
.	.	.	O

On	on	IN	O
the	the	DT	O
contrary	contrary	NN	O
,	,	,	O
the	the	DT	O
compound	compound	NN	O
9âh	9âh	CD	O
with	with	IN	O
3-s	3-s	CD	O
-	-	HYPH	O
butoxy	butoxy	JJ	O
phenyl	phenyl	NN	O
exhibited	exhibit	VBN	O
low	low	JJ	O
enzymatic	enzymatic	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
IC50	IC50	NNP	O
>	>	XX	O
1000ânM	1000ânm	CD	O
.	.	.	O

Meanwhile	meanwhile	RB	O
,	,	,	O
the	the	DT	O
compound	compound	NN	O
with	with	IN	O
3-COOMe	3-coome	CD	O
-	-	HYPH	O
phenyl	phenyl	NN	O
9âh	9âh	CD	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
77.7ânM	77.7ânM	NNP	O
,	,	,	O
3,5-dichloro	3,5-dichloro	NNP	O
-	-	HYPH	O
phenyl	phenyl	NN	O
9k	9k	NN	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
67.2ânM	67.2ânM	NNP	O
,	,	,	O
2,5-dichloro	2,5-dichloro	CD	O
-	-	HYPH	O
phenyl	phenyl	NN	O
9âl	9âl	CD	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
50.6ânM	50.6ânm	CD	O
,	,	,	O
2,3-dichloro	2,3-dichloro	CD	O
-	-	HYPH	O
phenyl	phenyl	NNP	O
9âm	9âm	CD	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
44.8ânM	44.8ânM	NNP	O
,	,	,	O
2,6-methyl	2,6-methyl	CD	O
-	-	HYPH	O
phenyl	phenyl	NN	O
9q	9q	NN	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
41.7ânM	41.7ânM	NNP	O
,	,	,	O
shown	show	VBN	O
moderate	moderate	JJ	O
FGFR1	fgfr1	CD	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
.	.	.	O

On	on	IN	O
the	the	DT	O
other	other	JJ	O
hand	hand	NN	O
,	,	,	O
compounds	compound	NNS	O
containing	contain	VBG	O
a	a	DT	O
substituent	substituent	NN	O
either	either	CC	O
the	the	DT	O
electron	electron	NN	O
-	-	HYPH	O
withdrawing	withdrawing	NN	O
or	or	CC	O
electron	electron	NN	O
-	-	HYPH	O
donating	donate	VBG	O
group	group	NN	O
at	at	IN	O
para	para	NNP	O
-	-	HYPH	O
position	position	NN	O
,	,	,	O
were	be	VBD	O
significant	significant	JJ	O
decreasing	decrease	VBG	O
their	-PRON-	PRP$	O
activities	activity	NNS	O
9d	9d	NN	O
vs	vs	IN	O
9i	9i	NNS	O
;	;	:	O
9k	9k	NNS	O
,	,	,	O
9âl	9âl	CD	O
and	and	CC	O
9âm	9âm	CD	O
vs	vs	IN	O
9n	9n	CD	O
;	;	:	O
9âm	9âm	CD	O
vs	vs	IN	O
9p	9p	NN	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
the	the	DT	O
additional	additional	JJ	O
halogen	halogen	NN	O
atoms	atom	NNS	O
on	on	IN	O
phenyl	phenyl	NNP	O
might	may	MD	O
be	be	VB	O
helpful	helpful	JJ	O
to	to	TO	O
improve	improve	VB	O
physicochemical	physicochemical	JJ	O
properties	property	NNS	O
and	and	CC	O
enhance	enhance	VB	O
the	the	DT	O
cell	cell	NN	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activities	activity	NNS	O
.	.	.	O

Thus	thus	RB	O
,	,	,	O
the	the	DT	O
compound	compound	NN	O
9o	9o	NN	O
IC50	IC50	NNP	O
=	=	SYM	O
5.5ânM	5.5ânM	NNP	O
containing	contain	VBG	O
a	a	DT	O
fluorine	fluorine	NN	O
atom	atom	NN	O
at	at	IN	O
the	the	DT	O
para	para	NN	O
-	-	HYPH	O
position	position	NN	O
of	of	IN	O
phenyl	phenyl	NNP	O
showed	show	VBD	O
better	well	JJR	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
than	than	IN	O
their	-PRON-	PRP$	O
counterparts	counterpart	NNS	O
lack	lack	NN	O
of	of	IN	O
these	these	DT	O
atoms	atom	NNS	O
9d	9d	NN	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
15.0ânM	15.0ânm	CD	O
.	.	.	O

Structures	structure	NNS	O
and	and	CC	O
activities	activity	NNS	O
of	of	IN	O
indazole	indazole	NN	O
derivatives	derivative	NNS	O
9eât	9eât	CD	O
.	.	.	O

The	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
are	be	VBP	O
shown	show	VBN	O
as	as	IN	O
the	the	DT	O
average	average	JJ	O
values	value	NNS	O
from	from	IN	O
two	two	CD	O
separate	separate	JJ	O
experiments	experiment	NNS	O
.	.	.	O

SNU-16	snu-16	CD	O
is	be	VBZ	O
FGFR2-amplified	FGFR2-amplified	NNP	O
cell	cell	NN	O
type	type	NN	O
.	.	.	O

âNAâ	âNAâ	NFP	O
means	mean	VBZ	O
IC50	IC50	NNP	O
>	>	XX	O
5âÎ¼M.	5âÎ¼M.	.	O
The	the	DT	O
active	active	JJ	O
compounds	compound	NNS	O
9e	9e	NNS	O
,	,	,	O
9f	9f	CD	O
,	,	,	O
9âh	9âh	CD	O
,	,	,	O
9k	9k	CD	O
,	,	,	O
9âl	9âl	CD	O
,	,	,	O
9âm	9âm	CD	O
,	,	,	O
9o	9o	CD	O
and	and	CC	O
9q	9q	CD	O
were	be	VBD	O
also	also	RB	O
selected	select	VBN	O
for	for	IN	O
further	further	JJ	O
evaluation	evaluation	NN	O
of	of	IN	O
their	-PRON-	PRP$	O
cellular	cellular	JJ	O
potencies	potency	NNS	O
.	.	.	O

Although	although	IN	O
,	,	,	O
the	the	DT	O
FGFR1	fgfr1	CD	O
enzyme	enzyme	VBZ	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
of	of	IN	O
compound	compound	NN	O
9âh	9âh	CD	O
and	and	CC	O
9j	9j	CD	O
were	be	VBD	O
higher	high	JJR	O
than	than	IN	O
that	that	DT	O
of	of	IN	O
9d	9d	NN	O
,	,	,	O
while	while	IN	O
the	the	DT	O
cell	cell	NN	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activities	activity	NNS	O
were	be	VBD	O
similar	similar	JJ	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
compound	compound	VB	O
9o	9o	JJ	O
bearing	bear	VBG	O
a	a	DT	O
fluorine	fluorine	NN	O
atom	atom	NN	O
at	at	IN	O
meta	meta	JJ	O
-	-	HYPH	O
position	position	NN	O
of	of	IN	O
phenyl	phenyl	NNP	O
resulted	result	VBD	O
in	in	IN	O
1.4-fold	1.4-fold	CD	O
enhancement	enhancement	NN	O
of	of	IN	O
the	the	DT	O
cellular	cellular	JJ	O
inhibition	inhibition	NN	O
,	,	,	O
which	which	WDT	O
exhibited	exhibit	VBD	O
the	the	DT	O
best	good	JJS	O
enzyme	enzyme	NNS	O
and	and	CC	O
cellular	cellular	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
of	of	IN	O
these	these	DT	O
indazole	indazole	NN	O
compounds	compound	VBZ	O
9e	9e	NNP	O
-	-	HYPH	O
t	t	NN	O
.	.	.	O

As	as	IN	O
the	the	DT	O
above	above	RB	O
reported	report	VBN	O
,	,	,	O
R1	R1	NNP	O
group	group	NN	O
located	locate	VBN	O
at	at	IN	O
the	the	DT	O
solvent	solvent	NN	O
region	region	NN	O
of	of	IN	O
the	the	DT	O
target	target	NN	O
protein	protein	NN	O
,	,	,	O
which	which	WDT	O
might	may	MD	O
be	be	VB	O
help	help	NN	O
to	to	TO	O
improve	improve	VB	O
membrane	membrane	NN	O
permeability	permeability	NN	O
and	and	CC	O
enhance	enhance	VB	O
cell	cell	NN	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activities	activity	NNS	O
.	.	.	O

Another	another	DT	O
six	six	CD	O
compounds	compound	VBZ	O
9âu	9âu	CD	O
-	-	HYPH	O
z	z	NNP	O
were	be	VBD	O
designed	design	VBN	O
,	,	,	O
prepared	prepare	VBN	O
and	and	CC	O
evaluated	evaluate	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
biological	biological	JJ	O
activities	activity	NNS	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
of	of	IN	O
inhibition	inhibition	NN	O
of	of	IN	O
FGFR1	FGFR1	NNP	O
assay	assay	NNP	O
revealed	reveal	VBD	O
that	that	IN	O
2S	2S	NNP	O
,	,	,	O
6âR)-2,6-dimethyl-1-phenylpiperazine	6âR)-2,6-dimethyl-1-phenylpiperazine	NNP	O
9v	9v	CD	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
13.2ânM	13.2ânM	NNP	O
,	,	,	O
and	and	CC	O
N	N	NNP	O
-	-	HYPH	O
methyl-4-phenylpiperazine	methyl-4-phenylpiperazine	NNP	O
9ây	9ây	CD	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
10.2ânM	10.2ânm	CD	O
led	lead	VBD	O
to	to	IN	O
slight	slight	JJ	O
reduction	reduction	NN	O
potency	potency	NN	O
comparing	compare	VBG	O
to	to	IN	O
N	N	NNP	O
-	-	HYPH	O
ethyl-4-phenylpiperazine	ethyl-4-phenylpiperazine	NNP	O
9o	9o	CD	O
,	,	,	O
IC50	IC50	NNP	O
=	=	SYM	O
5.5ânM	5.5ânM	NNP	O
,	,	,	O
while	while	IN	O
introducing	introduce	VBG	O
of	of	IN	O
a	a	DT	O
1-benzyl-4-methylpiperazine	1-benzyl-4-methylpiperazine	CD	O
group	group	NN	O
9x	9x	NN	O
,	,	,	O
IC50	IC50	NNP	O
>	>	XX	O
1000ânM	1000ânm	CD	O
demonstrated	demonstrate	VBD	O
poor	poor	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
FGFR1	fgfr1	CD	O
enzyme	enzyme	NNS	O
.	.	.	O

Meanwhile	meanwhile	RB	O
,	,	,	O
the	the	DT	O
FGFR1	fgfr1	CD	O
inhibitory	inhibitory	JJ	O
activities	activity	NNS	O
of	of	IN	O
compounds	compound	NNS	O
9âu	9âu	CD	O
,	,	,	O
9w	9w	CD	O
and	and	CC	O
9z	9z	CD	O
were	be	VBD	O
enhanced	enhance	VBN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
lead	lead	JJ	O
compound	compound	NN	O
9âu	9âu	CD	O
was	be	VBD	O
1.5-fold	1.5-fold	CD	O
enhancement	enhancement	NN	O
.	.	.	O

More	more	RBR	O
importantly	importantly	RB	O
,	,	,	O
the	the	DT	O
cellular	cellular	JJ	O
potencies	potency	NNS	O
were	be	VBD	O
improved	improve	VBN	O
by	by	IN	O
introducing	introduce	VBG	O
various	various	JJ	O
R1	R1	NNP	O
group	group	NN	O
9âu	9âu	CD	O
,	,	,	O
9v	9v	NN	O
and	and	CC	O
9w	9w	CD	O
vs	vs	IN	O
9o	9o	CD	O
,	,	,	O
and	and	CC	O
among	among	IN	O
them	-PRON-	PRP	O
9âu	9âu	CD	O
exhibited	exhibit	VBD	O
the	the	DT	O
good	good	JJ	O
FGFR1	fgfr1	CD	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
and	and	CC	O
cell	cell	NN	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activity	activity	NN	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
we	-PRON-	PRP	O
selected	select	VBD	O
9âu	9âu	CD	O
as	as	IN	O
the	the	DT	O
lead	lead	JJ	O
compound	compound	NN	O
for	for	IN	O
further	further	JJ	O
pharmacological	pharmacological	JJ	O
research	research	NN	O
.	.	.	O

Structures	structure	NNS	O
and	and	CC	O
activities	activity	NNS	O
of	of	IN	O
indazole	indazole	NN	O
derivatives	derivative	VBZ	O
9âuâz	9âuâz	CD	O
.	.	.	O

The	the	DT	O
IC50	IC50	NNP	O
values	value	NNS	O
are	be	VBP	O
shown	show	VBN	O
as	as	IN	O
the	the	DT	O
average	average	JJ	O
values	value	NNS	O
from	from	IN	O
two	two	CD	O
separate	separate	JJ	O
experiments	experiment	NNS	O
.	.	.	O

SNU-16	snu-16	CD	O
is	be	VBZ	O
FGFR2-amplified	FGFR2-amplified	NNP	O
cell	cell	NN	O
type	type	NN	O
.	.	.	O

âNAâ	âNAâ	NFP	O
means	mean	VBZ	O
IC50	IC50	NNP	O
>	>	XX	O
5âÎ¼M.	5âÎ¼M.	NNP	O
To	to	TO	O
identify	identify	VB	O
the	the	DT	O
kinase	kinase	NN	O
selectivity	selectivity	NN	O
of	of	IN	O
the	the	DT	O
lead	lead	JJ	O
compound	compound	NN	O
9âu	9âu	CD	O
,	,	,	O
the	the	DT	O
pharmacological	pharmacological	JJ	O
experiment	experiment	NN	O
was	be	VBD	O
first	first	RB	O
evaluated	evaluate	VBN	O
by	by	IN	O
testing	test	VBG	O
it	-PRON-	PRP	O
against	against	IN	O
our	-PRON-	PRP$	O
in	in	IN	O
-	-	HYPH	O
house	house	NN	O
panel	panel	NN	O
of	of	IN	O
tyrosine	tyrosine	NN	O
kinases	kinase	NNS	O
.	.	.	O

The	the	DT	O
results	result	NNS	O
were	be	VBD	O
summarised	summarise	VBN	O
in	in	IN	O
Table	table	NN	O
4	4	CD	O
,	,	,	O
9âu	9âu	CD	O
effectively	effectively	RB	O
inhibited	inhibit	VBD	O
the	the	DT	O
potent	potent	JJ	O
activities	activity	NNS	O
of	of	IN	O
FGFR1	fgfr1	CD	O
-	-	SYM	O
3	3	CD	O
with	with	IN	O
IC50	IC50	NNP	O
values	value	NNS	O
of	of	IN	O
3.3ânM	3.3ânm	CD	O
,	,	,	O
5.2ânM	5.2ânm	CD	O
and	and	CC	O
12.2ânM	12.2ânm	CD	O
,	,	,	O
respectively	respectively	RB	O
.	.	.	O

However	however	RB	O
,	,	,	O
9âu	9âu	CD	O
exhibited	exhibit	VBN	O
low	low	JJ	O
enzymatic	enzymatic	JJ	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
IC50	IC50	NNP	O
>	>	XX	O
1000ânM	1000ânm	CD	O
,	,	,	O
which	which	WDT	O
indicated	indicate	VBD	O
that	that	IN	O
9âu	9âu	CD	O
is	be	VBZ	O
a	a	DT	O
selective	selective	JJ	O
FGFR1	fgfr1	CD	O
-	-	SYM	O
3	3	CD	O
inhibitor	inhibitor	NN	O
.	.	.	O

The	the	DT	O
reason	reason	NN	O
was	be	VBD	O
that	that	IN	O
the	the	DT	O
sequence	sequence	NN	O
of	of	IN	O
FGFR1	FGFR1	NNP	O
-	-	SYM	O
3	3	CD	O
was	be	VBD	O
very	very	RB	O
similar	similar	JJ	O
,	,	,	O
while	while	IN	O
the	the	DT	O
sequence	sequence	NN	O
of	of	IN	O
FGFR4	fgfr4	NN	O
was	be	VBD	O
quite	quite	RB	O
different	different	JJ	O
.	.	.	O

Therefore	therefore	RB	O
,	,	,	O
the	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
FGFR1	fgfr1	CD	O
-	-	SYM	O
3	3	CD	O
inhibitor	inhibitor	NN	O
was	be	VBD	O
different	different	JJ	O
from	from	IN	O
FGFR4	fgfr4	NN	O
inhibitor	inhibitor	NN	O
,	,	,	O
and	and	CC	O
the	the	DT	O
pharmacophore	pharmacophore	NN	O
of	of	IN	O
FGFR4	FGFR4	NNP	O
inhibitor	inhibitor	NN	O
usually	usually	RB	O
contained	contain	VBD	O
an	an	DT	O
acrylamide	acrylamide	JJ	O
group	group	NN	O
.	.	.	O

Furthermore	furthermore	RB	O
,	,	,	O
IC50	IC50	NNP	O
values	value	NNS	O
for	for	IN	O
most	most	JJS	O
of	of	IN	O
kinases	kinase	NNS	O
were	be	VBD	O
greater	great	JJR	O
than	than	IN	O
1âÎ¼M	1âî¼m	CD	O
except	except	IN	O
for	for	IN	O
Flt-1	Flt-1	NNP	O
,	,	,	O
RET	RET	NNP	O
and	and	CC	O
c	c	NNP	O
-	-	HYPH	O
Src	Src	NNP	O
,	,	,	O
which	which	WDT	O
were	be	VBD	O
inhibited	inhibit	VBN	O
at	at	IN	O
sub	sub	JJ	O
-	-	JJ	O
micromolar	micromolar	JJ	O
concentrations	concentration	NNS	O
of	of	IN	O
the	the	DT	O
compound	compound	NN	O
.	.	.	O

As	as	IN	O
a	a	DT	O
result	result	NN	O
,	,	,	O
compound	compound	VB	O
9âu	9âu	CD	O
exhibited	exhibit	VBN	O
good	good	JJ	O
kinase	kinase	NN	O
selectivity	selectivity	NN	O
.	.	.	O

Selectivity	selectivity	NN	O
of	of	IN	O
9âu	9âu	CD	O
in	in	IN	O
a	a	DT	O
panel	panel	NN	O
of	of	IN	O
kinases	kinase	NNS	O
.	.	.	O

The	the	DT	O
docking	docking	NN	O
simulation	simulation	NN	O
was	be	VBD	O
performed	perform	VBN	O
to	to	TO	O
elucidate	elucidate	VB	O
the	the	DT	O
binding	bind	VBG	O
mode	mode	NN	O
of	of	IN	O
the	the	DT	O
various	various	JJ	O
scaffold	scaffold	JJ	O
derivatives	derivative	NNS	O
9d	9d	NNP	O
,	,	,	O
12a	12a	NNS	O
and	and	CC	O
18âb	18âb	CD	O
,	,	,	O
the	the	DT	O
potent	potent	JJ	O
indazole	indazole	JJ	O
inhibitor	inhibitor	NN	O
9e	9e	NNS	O
and	and	CC	O
9f	9f	CD	O
,	,	,	O
the	the	DT	O
inactive	inactive	JJ	O
inhibitor	inhibitor	NN	O
9âg	9âg	NN	O
with	with	IN	O
FGFR1	FGFR1	NNS	O
.	.	.	O

These	these	DT	O
compounds	compound	NNS	O
were	be	VBD	O
docked	dock	VBN	O
into	into	IN	O
the	the	DT	O
ATP	atp	NN	O
-	-	HYPH	O
binding	bind	VBG	O
pocket	pocket	NN	O
of	of	IN	O
FGFR1	FGFR1	NNS	O
.	.	.	O

As	as	IN	O
a	a	DT	O
result	result	NN	O
,	,	,	O
the	the	DT	O
core	core	NN	O
indazole	indazole	NN	O
ring	ring	NN	O
of	of	IN	O
compound	compound	NNP	O
9d	9d	NNP	O
was	be	VBD	O
entered	enter	VBN	O
the	the	DT	O
adenine	adenine	NN	O
region	region	NN	O
by	by	IN	O
forming	form	VBG	O
the	the	DT	O
essential	essential	JJ	O
H	h	NN	O
-	-	HYPH	O
bond	bond	NN	O
interaction	interaction	NN	O
with	with	IN	O
hinge	hinge	NN	O
residue	residue	NN	O
Glu562	Glu562	NNS	O
and	and	CC	O
Ala564	ala564	CD	O
,	,	,	O
while	while	IN	O
the	the	DT	O
N	N	NNP	O
-	-	HYPH	O
H	H	NNP	O
of	of	IN	O
indazole	indazole	NN	O
scaffold	scaffold	NN	O
formed	form	VBD	O
H	h	NN	O
-	-	HYPH	O
bond	bond	NN	O
with	with	IN	O
Glu562	glu562	CD	O
,	,	,	O
and	and	CC	O
the	the	DT	O
nitrogen	nitrogen	NN	O
atom	atom	NN	O
of	of	IN	O
indazole	indazole	NN	O
scaffold	scaffold	NN	O
and	and	CC	O
N	N	NNP	O
-	-	HYPH	O
H	H	NNP	O
of	of	IN	O
amide	amide	NN	O
formed	form	VBD	O
another	another	DT	O
two	two	CD	O
hydrogen	hydrogen	NN	O
bond	bond	NN	O
with	with	IN	O
Ala564	ala564	CD	O
Figure	figure	NN	O
3	3	CD	O
.	.	.	O

Meanwhile	meanwhile	RB	O
,	,	,	O
the	the	DT	O
3-methoxy	3-methoxy	CD	O
phenyl	phenyl	NNP	O
group	group	NN	O
occupied	occupy	VBD	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
area	area	NN	O
I	I	NNP	O
,	,	,	O
and	and	CC	O
hydrophobic	hydrophobic	VBD	O
interact	interact	NNP	O
with	with	IN	O
the	the	DT	O
lipophilic	lipophilic	JJ	O
residue	residue	NN	O
Leu547	leu547	CD	O
,	,	,	O
Val561	val561	CD	O
and	and	CC	O
Phe	Phe	NNP	O
642	642	CD	O
.	.	.	O

However	however	RB	O
,	,	,	O
while	while	IN	O
the	the	DT	O
hetero	hetero	NNP	O
aromatic	aromatic	NNP	O
rings	ring	NNS	O
were	be	VBD	O
converted	convert	VBN	O
to	to	IN	O
1H-1,2,4-triazole	1h-1,2,4-triazole	CD	O
or	or	CC	O
benzothiazole	benzothiazole	NN	O
,	,	,	O
there	there	EX	O
was	be	VBD	O
weakly	weakly	RB	O
H	H	NNP	O
-	-	HYPH	O
bond	bond	NN	O
interaction	interaction	NN	O
with	with	IN	O
Ala564	ala564	CD	O
,	,	,	O
and	and	CC	O
no	no	DT	O
H	h	NN	O
-	-	HYPH	O
bond	bond	NN	O
interaction	interaction	NN	O
with	with	IN	O
Glu562	glu562	CD	O
Figure	figure	NN	O
3	3	CD	O
.	.	.	O

Besides	besides	RB	O
,	,	,	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
group	group	NN	O
I	-PRON-	PRP	O
was	be	VBD	O
deviated	deviate	VBN	O
from	from	IN	O
hydrophobic	hydrophobic	NN	O
pocket	pocket	NN	O
.	.	.	O

The	the	DT	O
above	above	JJ	O
docking	docking	NN	O
results	result	NNS	O
might	may	MD	O
explain	explain	VB	O
why	why	WRB	O
the	the	DT	O
triazole	triazole	NN	O
and	and	CC	O
benzothiazole	benzothiazole	JJ	O
derivatives	derivative	NNS	O
lost	lose	VBD	O
their	-PRON-	PRP$	O
biological	biological	JJ	O
activities	activity	NNS	O
12a	12a	NNS	O
docking	docking	NN	O
score	score	NN	O
:	:	:	O
6.380	6.380	CD	O
,	,	,	O
18âb	18âb	CD	O
docking	docking	NN	O
score	score	NN	O
:	:	:	O
6.588	6.588	CD	O
.	.	.	O

The	the	DT	O
docking	docking	NN	O
mode	mode	NN	O
of	of	IN	O
compound	compound	NN	O
9d	9d	NN	O
,	,	,	O
12a	12a	NNS	O
,	,	,	O
and	and	CC	O
18âb	18âb	CD	O
.	.	.	O

Superposed	superpose	VBN	O
docking	docking	NN	O
poses	pose	NNS	O
of	of	IN	O
9e	9e	NN	O
,	,	,	O
9f	9f	CD	O
,	,	,	O
and	and	CC	O
9âg	9âg	CD	O
.	.	.	O

Additionally	additionally	RB	O
,	,	,	O
the	the	DT	O
methoxy	methoxy	JJ	O
group	group	NN	O
of	of	IN	O
9d	9d	NNP	O
was	be	VBD	O
inserted	insert	VBN	O
into	into	IN	O
a	a	DT	O
small	small	JJ	O
hydrophobic	hydrophobic	JJ	O
cavity	cavity	NN	O
of	of	IN	O
the	the	DT	O
hydrophobic	hydrophobic	JJ	O
area	area	NN	O
I.	I.	NNP	O
While	while	IN	O
this	this	DT	O
cavity	cavity	NN	O
could	could	MD	O
contain	contain	VB	O
a	a	DT	O
certain	certain	JJ	O
size	size	NN	O
of	of	IN	O
lipophilic	lipophilic	JJ	O
group	group	NN	O
,	,	,	O
thus	thus	RB	O
the	the	DT	O
ethyloxy	ethyloxy	JJ	O
substituent	substituent	NN	O
of	of	IN	O
9e	9e	NN	O
and	and	CC	O
the	the	DT	O
iso	iso	NNP	O
-	-	HYPH	O
propyxoy	propyxoy	NNP	O
substituent	substituent	NN	O
of	of	IN	O
9f	9f	CD	O
were	be	VBD	O
more	more	RBR	O
appropriate	appropriate	JJ	O
to	to	IN	O
this	this	DT	O
hydrophobic	hydrophobic	JJ	O
cavity	cavity	NN	O
,	,	,	O
meanwhile	meanwhile	RB	O
9e	9e	NNS	O
and	and	CC	O
9f	9f	CD	O
shown	show	VBD	O
more	more	RBR	O
potent	potent	JJ	O
FGFR1	fgfr1	CD	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
than	than	IN	O
9d	9d	NN	O
.	.	.	O

However	however	RB	O
,	,	,	O
the	the	DT	O
cavity	cavity	NN	O
could	could	MD	O
not	not	RB	O
accommodate	accommodate	VB	O
large	large	JJ	O
volume	volume	NN	O
groups	group	NNS	O
,	,	,	O
including	include	VBG	O
the	the	DT	O
sec	sec	NNP	O
-	-	HYPH	O
butoxy	butoxy	NNP	O
group	group	NN	O
9âg	9âg	CD	O
docking	docking	NN	O
score	score	NN	O
:	:	:	O
5.668	5.668	CD	O
,	,	,	O
IC50	IC50	NNP	O
>	>	XX	O
1000ânM	1000ânm	CD	O
.	.	.	O

The	the	DT	O
molecular	molecular	JJ	O
simulation	simulation	NN	O
results	result	NNS	O
may	may	MD	O
further	further	RB	O
confirm	confirm	VB	O
the	the	DT	O
inhibitory	inhibitory	JJ	O
potency	potency	NN	O
of	of	IN	O
9e	9e	NNP	O
and	and	CC	O
9f	9f	CD	O
against	against	IN	O
FGFR1	fgfr1	CD	O
,	,	,	O
and	and	CC	O
the	the	DT	O
9âg	9âg	CD	O
was	be	VBD	O
inactive	inactive	JJ	O
Figure	figure	NN	O
3	3	CD	O
.	.	.	O

In	in	IN	O
summary	summary	NN	O
,	,	,	O
we	-PRON-	PRP	O
designed	design	VBD	O
three	three	CD	O
novel	novel	JJ	O
series	series	NN	O
of	of	IN	O
FGFR1	FGFR1	NNP	O
inhibitors	inhibitor	NNS	O
bearing	bear	VBG	O
indazole	indazole	NN	O
,	,	,	O
benzothiazole	benzothiazole	NNP	O
,	,	,	O
and	and	CC	O
1H-1,2,4-triazole	1h-1,2,4-triazole	CD	O
scaffold	scaffold	NN	O
via	via	IN	O
fragment	fragment	NN	O
-	-	HYPH	O
based	base	VBN	O
virtual	virtual	JJ	O
screening	screening	NN	O
.	.	.	O

Interestingly	interestingly	RB	O
,	,	,	O
33	33	CD	O
new	new	JJ	O
compounds	compound	NNS	O
were	be	VBD	O
synthesised	synthesise	VBN	O
and	and	CC	O
evaluated	evaluate	VBN	O
for	for	IN	O
their	-PRON-	PRP$	O
inhibitory	inhibitory	JJ	O
activity	activity	NN	O
against	against	IN	O
FGFR1	FGFR1	NNS	O
.	.	.	O

Initially	initially	RB	O
,	,	,	O
the	the	DT	O
indazole	indazole	NN	O
derivative	derivative	NNP	O
9d	9d	NNP	O
was	be	VBD	O
identified	identify	VBN	O
as	as	IN	O
a	a	DT	O
promising	promising	JJ	O
FGFR1	fgfr1	NN	O
inhibitor	inhibitor	NN	O
,	,	,	O
with	with	IN	O
the	the	DT	O
good	good	JJ	O
enzymatic	enzymatic	JJ	O
inhibition	inhibition	NN	O
IC50	IC50	NNP	O
=	=	SYM	O
15.0ânM	15.0ânm	CD	O
and	and	CC	O
modest	modest	JJ	O
anti	anti	JJ	O
-	-	JJ	O
proliferative	proliferative	JJ	O
activity	activity	NN	O
IC50	IC50	NNP	O
=	=	SYM	O
785.8ânM	785.8ânm	CD	O
.	.	.	O

Then	then	RB	O
,	,	,	O
the	the	DT	O
hit	hit	NN	O
9d	9d	NN	O
was	be	VBD	O
further	further	RB	O
optimised	optimise	VBN	O
,	,	,	O
through	through	IN	O
two	two	CD	O
rounds	round	NNS	O
of	of	IN	O
optimisation	optimisation	NN	O
,	,	,	O
the	the	DT	O
compound	compound	NN	O
9âu	9âu	CD	O
stood	stand	VBD	O
out	out	RP	O
as	as	IN	O
the	the	DT	O
most	most	RBS	O
potent	potent	JJ	O
FGFR1	FGFR1	NNP	O
inhibitors	inhibitor	NNS	O
with	with	IN	O
the	the	DT	O
best	good	JJS	O
enzyme	enzyme	NNS	O
inhibitory	inhibitory	NN	O
IC50	IC50	NNP	O
=	=	SYM	O
3.3ânM	3.3ânM	NNP	O
and	and	CC	O
cellular	cellular	JJ	O
activity	activity	NN	O
IC50	IC50	NNP	O
=	=	SYM	O
468.2ânM	468.2ânm	CD	O
.	.	.	O

Moreover	moreover	RB	O
,	,	,	O
9âu	9âu	NNP	O
also	also	RB	O
exhibited	exhibit	VBD	O
good	good	JJ	O
kinase	kinase	NN	O
selectivity	selectivity	NN	O
.	.	.	O

Meanwhile	meanwhile	RB	O
,	,	,	O
the	the	DT	O
docking	docking	NN	O
study	study	NN	O
was	be	VBD	O
performed	perform	VBN	O
to	to	TO	O
investigate	investigate	VB	O
the	the	DT	O
putative	putative	JJ	O
interaction	interaction	NN	O
mechanism	mechanism	NN	O
with	with	IN	O
the	the	DT	O
FGFR1	fgfr1	CD	O
target	target	NN	O
.	.	.	O

Further	further	JJ	O
studies	study	NNS	O
on	on	IN	O
the	the	DT	O
structural	structural	JJ	O
optimisation	optimisation	NN	O
and	and	CC	O
biological	biological	JJ	O
evaluation	evaluation	NN	O
of	of	IN	O
9âu	9âu	CD	O
are	be	VBP	O
currently	currently	RB	O
underway	underway	JJ	O
in	in	IN	O
our	-PRON-	PRP$	O
laboratory	laboratory	NN	O
.	.	.	O

Our	-PRON-	PRP$	O
study	study	NN	O
would	would	MD	O
provide	provide	VB	O
a	a	DT	O
basis	basis	NN	O
for	for	IN	O
discovering	discover	VBG	O
novel	novel	JJ	O
FGFR1	FGFR1	NNS	O
inhibitors	inhibitor	NNS	O
.	.	.	O

